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Abstract This updated systematic review assesses the effects of pharmacological inter-
ventions for drug-using offenders.
Methods Systematic review protocols and conventions of the Cochrane Collaboration
were followed to identify eligible studies. Studies were pooled in a meta-analysis to
assess the impact of pharmacological interventions on drug use and criminal activity.
An economic appraisal was conducted.
Results The search strategies identified 22 studies containing 4372 participants. Meta-
analyses revealed a small statistically significant mean difference favouring pharmaco-
logical interventions relative to psychological interventions in reducing drug use and
criminal activity. When comparing the drugs to one another there were no significant
differences between those included (methadone versus buprenorphine, naltrexone and
cyclazocine).
Conclusion Overall, the findings of this review suggest that methadone and naltrexone
may have some impact on reducing drug use and reincarceration. Individual pharma-
cological drugs had differing (generally non-significant) effects. One study identified
serious adverse events. Three studies reported cost and consequences information
sufficient to conduct a full economic analysis but this was not comprehensive enough
to be able to make judgements across all treatment options. Full economic analyses
should be encouraged. The study findings were limited mainly to male adult offenders.
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Introduction
Offenders as a socially excluded group of people demonstrate significant drug use and
subsequent health problems. Studies investigating the prevalence of drug dependence
in UK prisons report variable figures of 10% (Gunn et al., 1991), 39% (Brooke et al.,
1996) and 33% (Mason et al., 1997). In a review article, the estimated prevalence of
drug abuse among male and female prisoners was estimated to be 10 to 48% and 30 to
60%, respectively (Fazel et al., 2006). A recent survey carried out on the Swedish
criminal justice system found that 70% of all individuals had substance abuse problems
(including alcohol, drugs or both), with a slightly lower percentage among females
compared with the whole group (67%) (Klientkartlaggningen, 2015). These numbers
can be compared with the general population in Sweden where 1% of all men and 0.5%
of all women fulfil the criteria for drug dependence or abuse (Ramstedt et al., 2013).
Similar trends have been reported elsewhere. In France, 30% of prison inmates are
heroin addicted, and in Australia, 59% of prison inmates report injecting (primarily
heroin) drug use histories. In 2018 in the USA, an estimated 6,410,000 persons were
held in prisons or jails, or were on probation or parole (Maruschak and Minton, 2020).
Of the prison population, 85% are likely to have an active substance use disorder or
were incarcerated for a crime involving drugs or drug use according to the US National
Institute on Drug Abuse (National Institute on Drug Abuse (NIDA), 2020). In the US, it
is recognised that many offenders need treatment to tackle their drug use (Lo and
Stephens, 2000). The link between drug use, subsequent health, social and crimino-
logical consequences is well documented in the literature (Michel and Maguet, 2005),
and offenders have a high risk of death from opioid overdose within 2 weeks of release
from prison (Binswanger et al., 2007, Bird and Hutchinson, 2003, Kinner et al., 2013,
Merrall et al., 2010). Substance use disorders are linked to criminal behaviour and are a
significant burden on the criminal justice system. Approximately 30% of acquisitive
crime is committed by individuals supporting drug use with the use of criminal acts
(Magura et al., 1995).
Internationally, methadone maintenance has been the primary choice for chronic
opioid dependence in prisons and jails, including those in the Netherlands, Australia,
Spain and Canada. As a result, it is increasingly implemented in the criminal justice
setting (Moller et al., 2007, Stallwitz and Stover, 2007) with the exception of the US
which has not generally endorsed the use of methadone treatment. For example, of the
30,000 individuals a year who enter prison or jail nearly 90% of those receiving
prescribed methadone are forced to stop or taper off this treatment (Fiscella et al.,
2004. Reasons for this lack of expansion suggest that public opinion and that of the
criminal justice system providers consider methadone treatment as substituting one
addiction for another. In contrast, buprenorphine appears not to carry the same social
stigma associated with methadone treatment and has been used in France, Austria and
Puerto Rico (Catania, 2003, Garcia et al., 2007, Gordon et al., 2017, Reynaud-Maurupt
et al., 2005). This is noted because unlike methadone it can be administered on alternate
days, a feature that would make buprenorphine use more efficient in correctional
settings than methadone (Garcia et al., 2007). Naltrexone treatment has shown some
promising findings, but associated problems surrounding high attrition and low med-
ication compliance in the community and high mortality rates pose concerns (Gibson
and Degenhardt, 2007, Minozzi et al., 2011). In 2005 naloxone was added to the UK’s
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exempt list of prescription-only medicines that could be administered to save life in an
emergency to reverse heroin/opioid overdose (Strang et al., 2006). Use of extended-
release naltrexone may also be appealing and beneficial to people who are unlikely to
access opioid-agonist maintenance treatment or who prefer a relapse-prevention treat-
ment (Lee et al., 2016). Trials conducted in the criminal justice setting are still lacking,
and continuity of care is considered crucial in the treatment of drug-using offenders
who transition between prison and the community.
A growing body of evidence shows the effects of pharmacological interventions for
drug use among the general population (see Table 1 for a summary of the evidence).
Existing reviews have focused on naltrexone maintenance treatment for opioid depen-
dence (Amato et al., 2005, Lobmaier et al., 2008, Minozzi et al., 2011), the efficacy of
methadone (Faggiano et al., 2003, Marsch, 1998, Mattick et al., 2009) and
buprenorphine maintenance (Mattick et al., 2009). Recent guidance has been provided
from the National Institute for Health and Clinical Excellence (NICE) on evidence-
based use of naltrexone, methadone and buprenorphine for the management of opioid
dependence (National Institute for Health and Care Excellence (NICE), 2007a, Nation-
al Institute for Health and Care Excellence (NICE), 2007b, National Institute for Health
and Care Excellence (NICE), 2019). Five Cochrane reviews (including 52 studies)
reported on the effectiveness of opiate methadone therapies (Amato et al., 2005).
Findings showed that methadone maintenance therapies at appropriate doses were most
effective in retaining participants in treatment and in suppressing heroin use, but
evidence of effectiveness for other relevant outcome measures such as criminal activity
was weak and was not systematically evaluated. Naloxone use is also found to work in
a similar manner by blocking the euphoria (reinforcement) sought by the user and
thereby reducing the drug-seeking behaviour and diminishing the risk of physical
dependence of heroin use (Kurland et al., 1975). Extended-release naltrexone uses
the same mechanism as naloxone but gradually releases a sufficient amount to block
the euphoria up to 1 month after an injection (Lee et al., 2016).
Systematic reviews evaluating treatment programmes for offender populations have
focused on evaluating treatments in one setting such as community-based programmes
(Mitchell et al., 2012a, Mitchell et al., 2012b), or have based their evidence on literature
from one country (Chanhatasilpa et al., 2000, Egg et al., 2000), or a number of specific
treatments (Mitchell et al., 2006). Pharmacological systematic reviews of offender
treatment appear to be sparse. We identified two previous reviews: one focusing on
specific drug- and property-related criminal behaviours in methadone maintenance
treatment (Marsch, 1998), and one an evaluation of the effectiveness of opioid main-
tenance treatment (OMT) in prison and post release (Hedrich et al., 2012). The latter of
these two reviews identified six experimental studies up until January 2011 (Hedrich
et al., 2012). The authors found that OMT in prison was significantly associated with
reduced heroin use, injecting and syringe sharing. The use of pre-release OMT was also
found to have important implications for associated treatment uptake after release, but
the impact on criminal activity was equivocal. Similar findings have been shown with
the use of extended-release naltrexone (XR-NTX) which showed that use of XR-NTX
before release might reduce opioid overdose, increase abstinence and antagonist
medication coverage during the high-risk initial weeks after release in comparison with
referral for XR-NTX treatment in the community after release (Friedmann et al., 2018).
Many people under the care of the criminal justice system have a drug misuse
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Table 1 Evidence on pharmacological interventions in the general population
Pharmacological
intervention





Methadone is an agonist that activates opioid receptors.
Methadone maintenance treatment can keep
heroin-dependent
people in treatment
and help them reduce
their use of heroin. It
is a heroin replacement





dose 10–30 mg per




Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance
therapy versus no opioid replacement therapy for opioid dependence.
Cochrane Database of Systematic Reviews 2009, Issue 3. Art.





Buprenorphine Buprenorphine is a partial agonist that activates opioid
receptors but with a diminished response.
Buprenorphine is effective in the maintenance treatment
of heroin-dependent people, at any dose above 2 mg.
It suppresses illicit opioid use (at doses 16 mg or
greater). Compared with methadone, buprenorphine
retains fewer people when doses are flexibly
delivered and at low fixed doses. At fixed medium or
higher doses, buprenorphine and methadone are
equally effective in terms of retention in treatment
and suppression of illicit opioid use.
Buprenorphine may be preferred to methadone to avoid
unwanted effects such as nausea, vomiting,
constipation and drowsiness, mind “clouding” sore
leg muscles.
Buprenorphine has less overdose potential.
Flexible dosage: Initially
0.8–4 mg for 1 dose on
the first day, adjusted
in steps of 2–4 mg
daily if required; usual
dose 12–24 mg daily;
maximum 32 mg per
day.
The drug can be taken
once every 2 days.
Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance
versus placebo or methadone maintenance for opioid dependence.
Cochrane Database of Systematic Reviews 2014, Issue 2.
Art. No.: CD002207. DOI: https://doi.org/10.1002/14651858.CD002207.
pub4.
Accessed 29 November 2020.
















Effectiveness summary Admini s t ra t i on and
dosage
Evidence sources
Buprenorphine is also available in combination with
naloxone (0.5–8 mg). The addition of naloxone
reduces the abuse potential.
Naltrexone Naltrexone is an antagonist which blocks the opioid
receptor and reduces cravings and urges to use
opioids. It does not produce euphoria and it is not
addictive.
There is inadequate evidence to support its use alone as a
maintenance treatment for opioid dependence. It may
be effective as a therapy for highly motivated and
well-supported people who prefer to follow an
abstinence programme to stay off opioids entirely.
Day 1: 25 mg
Day 2 onwards: 50 mg
daily
The total weekly dose
may be divided and
taken on 3 days of the
week to improve
compliance.
Minozzi S, Amato L, Vecchi S, Davoli M, Kirchmayer U, Verster A.
Oral naltrexone maintenance treatment for opioid dependence.
Cochrane Database of Systematic Reviews 2011, Issue 4.
Art. No.: CD001333. DOI: https://doi.org/10.1002/14651858.CD001333.
pub4.
Accessed 29 November 2020.
NICE. Naltrexone for the management of opioid dependence








As a class, a Cochrane review indicates that there is no
evidence that anticonvulsants are effective in the
treatment of cocaine dependence.
However, vigabatrin (off-label in many countries) has
been used to help with withdrawal from
benzodiazepines, cocaine and other stimulants, in
terms of reducing the frequency and severity of
seizures. Itis also used to reduce cravings and relapses
due to cravings.
50 mg twice a day Minozzi S,Cinquini M,Amato L,Davoli M,Farrell MF,Pani PP,Vecchi
S.Anticonvulsants for cocaine dependence. Cochrane Database of
Systematic Reviews 2015, Issue 4. Art. No.: CD006754.
DOI: https://doi.org/10.1002/14651858.CD006754.pub4.



























problem (Fazel et al., 2015). Whilst previous research has evaluated treatment
programmes for offenders more broadly, we know little about the challenges, treatment
and rehabilitation opportunities for offenders with pharmacological interventions aimed
at reducing drug use and criminal activity. This includes consideration of when and
where to offer treatment along the criminal justice pathway to maximise scarce
resources and maximise the effectiveness of treatment. We therefore believe that a
systematic review evaluating existing evidence from randomised controlled trials
(RCTs) might be helpful in identifying treatments for reducing drug use and criminal
activity in this vulnerable population. In principle, the RCT design eliminates the threat
to internal validity providing there is a sufficiently large number of units assigned as the
experimental and control conditions and methods to reduce bias are implemented
(Weisburd, 2010).
Given the importance of relating economic cost to a reduction in drug use and
related offending behaviour, good-quality economic evidence will help inform strate-
gies which represent the best use of limited resource (Higgins and Green, 2011). In this
review, we use the Drummond checklist (Drummond et al., 2005) to evaluate and
document the availability of resource information within the studies. The Drummond
checklist is a widely used tool to assess the quality of economic evaluation studies. It
assesses whether the study has a well-defined question, describes the competing
programmes, provides information on the effectiveness of the programmes, presents
all of the important and relevant costs and consequences for each programmes and
assesses whether costs and consequences of the programmes were accurately measured
and assigned credible values (and discounted appropriately). The checklist also assesses
any incremental cost-effectiveness analysis and sensitivity analysis around the costs
and consequences.
This systematic review has five primary research questions: (1) Do pharmacological
treatments for drug-using offenders reduce drug use? (2) Do pharmacological treat-
ments for drug-using offenders reduce criminal activity? (3) Does the treatment setting
(e.g. court, community, prison/secure establishment) affect outcome(s) of pharmaco-
logical treatments? (4) Does one type of pharmacological treatment perform better than
one other? (5) What are the comparative costs and cost-effectiveness of the available
interventions?
The systematic review was guided by a protocol which followed Cochrane ap-
proaches (Higgins and Green, 2011) to producing systematic reviews and an earlier
version has been published as a Cochrane review (Perry et al., 2015).
Methods
Studies included in the review had to meet a number of different criteria including the
study design, the type of participants and type of interventions. Studies had to report
pre-specified outcome measures to avoid the possibility of any subsequent bias in
choosing outcomes. The eligibility criteria are summarised below and described in
detail in Table 2.
Studies of illicit drug-using offenders were included in the review regardless of the
gender, age, psychiatric history or ethnicity of the study participants. Eligible interven-
tions were those designed, wholly or in part, to eliminate or prevent relapse to drug use
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Table 2 Summary of eligibility criteria
Inclusion criteria Exclusion criteria
Population • Illicit drug-using offenders were included in
the review regardless of gender, age, psy-
chiatric history, or ethnicity.
• Offenders were defined as individuals who
were involved in the Criminal Justice
System (CJS).
• Individuals could reside in special hospitals,
prisons, the community or who were
diverted from court or placed on arrest
referral schemes for treatment.
• The study setting could change throughout
the process of the study. For example,
people involved in the criminal justice
system could begin in prison but progress
through a work release project into a
community setting.
• Illicit drug use referred to individuals using
drugs occasionally or those who were
considered drug dependent.
Studies where part of the population were not
involved in the CJS.
Studies where the population were
alcohol-using as opposed to drug-using of-
fenders.
Intervention • Eligible interventions were those designed,
wholly or in part, to eliminate or prevent
relapse to drug use or criminal activity, or
both, among participants. We defined
relapse as individuals who may have
returned to an incarcerated setting, or had
subsequently been arrested or had relapsed
back into drug misuse, or both. We included
a range of different types of interventions in
the review.
• Experimental interventions included in the
review were any pharmacological
intervention (e.g. buprenorphine,
methadone).
• Control interventions eligible for the review
were no treatment or waiting list controls or
minimal and/or alternative treatment or
treatment as usual:
Minimal or alternative treatment might include
reporting use of a similar intervention but at
a less intense level, or using a different
theoretical approach but with the same
components and/or a different alternative
intervention.
Treatment as usual included any study that
reported a combination and/or component
of a (i) psychological based intervention
(e.g. anger management, motivational
interviewing, counselling, aggression
replacement, family therapy), (ii) an educa-
tional programme (e.g., health, substance
abuse education on risky behaviour) and or
(iii) life skills (e.g., financial planning, em-
ployment skills, computer skills and inter-
personal skills in interviews.
Studies of alcohol misuse only were not
eligible.
Studies of interventions with drug-using of-
fenders that were not focused on reducing
drug use.
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or criminal activity, or both, among participants. We defined relapse as individuals who
may have returned to an incarcerated setting, or had subsequently been arrested or had
relapsed back into drug misuse, or both. The primary outcomes investigated in the
review were drug use (self-reported drug use measures and biological drug use
measures), self-reported or official report of criminal activity (dichotomous and con-
tinuous data for arrests, reincarceration and parole violations) and adverse effects.
Secondary outcomes were resource use, costs and cost-effectiveness related to the
interventions, health care activity, criminal activity and productivity. Randomised
controlled trials (RCTs) were the eligible study design and no date or language limits
were applied to this review.
Search strategy for identification studies
The original searches for this review are reported in Perry (Perry et al., 2006, Perry
et al., 2015) and were subsequently updated in January 2018 to cover the period 2014
to 2018 and then updated further again in February 2019 to cover the period 2018 to
2019. We searched 12 databases: ASSIA, CINAHL, Cochrane Central Register of
Controlled Trials (CENTRAL), Criminal Justice Abstracts, Embase, Health Manage-
ment Information Consortium (HMIC), LILACS, MEDLINE, PAIS, PsycINFO, Sci-
ence Citation Index and Social Science Citation Index. The full search strategies for
each database are included in the Appendix.
To identify economic studies the topic specific searches of nine databases (ASSIA,
CENTRAL, CINAHL, Criminal Justice Abstracts, HMIC, LILACS, PAIS, Science
Citation Index, Social Science Citation Index) would have identified all potential RCTs
and economic evaluations included in the review. For the Embase, MEDLINE and
PsycINFO databases the search strategy incorporated an RCT filter to manage the
number of identified and relevant citations. This approach may have excluded potential
economic evaluations identified from these three databases and is therefore a limitation
of the review.
We developed individual search strategies for each database and made use of any
controlled vocabulary available for each database. We combined the subject search
Table 2 (continued)
Inclusion criteria Exclusion criteria
Outcomes
measures
• Primary outcomes were drug use measures
(self-reported drug use and biological drug
use), self-reported or official report of
criminal activity and adverse effects.
• Secondary outcomes were resource use, costs
and cost-effectiveness related to the




• RCTs were the eligible study design Studies that did not report data in a format that
allowed us to generate post
dichotomous/continuous outcomes
Limits • No date or language limits will be applied to
the searches
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terms with methodological search filters designed to identify RCTs, where available.
Additional search approaches were employed including checking the reference lists of
all retrieved articles for further references, searching catalogues of relevant organisa-
tions and contacting experts to obtain recommendations of other published or unpub-
lished studies relevant to the review. All references were managed in EndNote
(Clarivate, 2020) and subsequently Covidence (Veritas Health Innovation, 2013)
software.
Screening and coding process
A team of reviewers independently inspected the titles and abstracts for potential
inclusion in the review. Each record was assessed by two reviewers. The full articles
were obtained for each record which seemed likely to be eligible and the full text was
assessed for eligibility by two reviewers independently. In the case of disagreement, a
third independent reviewer helped to arbitrate. The screening criteria are provided in the
Appendix.
We used data extraction forms to standardise the reporting of data from all studies
obtained as potentially relevant. Two reviewers independently extracted data and
subsequently checked them for agreement. The narrative tables included a presentation
of the study details (e.g. author, year of publication and country of study origin), study
methods (e.g. random assignment), participants (e.g. number in sample, age, gender
and ethnicity), interventions (e.g. description, duration, intensity and setting), outcomes
(e.g. description, follow-up period and reporting mechanism) and notes (e.g. country
and funding).
Measures of treatment effect
Studies were combined as mean differences (MD) with 95% confidence intervals in the
meta-analyses for continuous outcomes measured on the same scale and standardised
mean difference (SMD) for outcomes measured on different scales. Higher scores for
continuous measures are representative of greater harm. We present dichotomous
outcomes as risk ratios (RR), with 95% confidence intervals (CIs).
Statistical issues
To avoid double counting of outcome measures (e.g. arrest and parole violation) and
follow-up time periods (e.g. 12, 18 months), we checked all trials to ensure that
multiple studies reporting the same evaluation did not contribute towards multiple
estimates of programme effectiveness. We followed Cochrane guidance and we com-
bined intervention and control groups to create a single pair-wise comparison. Where
this was not appropriate we selected one treatment arm and excluded the others. We
attempted to contact the study authors via email where missing data occurred in the
original publication.
We assessed heterogeneity using the I2 statistic and Chi2 statistic (Higgins and
Green, 2011). We regarded heterogeneity as substantial if the I2 was greater than
50% or the p value was lower than 0.10 for the Chi2 test for heterogeneity (Deeks
et al., 2017). Following specific Cochrane guidance (Deeks et al., 2017), we
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distinguished the following values to denote no important, moderate, substantial and
considerable heterogeneity, respectively: 0 to 40%, 30 to 60%, 50 to 90% and 75 to
100%.
Risk of bias assessment
The review team assessed risk of bias in all included studies using risk of bias
assessment criteria recommended in the Cochrane Handbook (Higgins and Green,
2011). Further detail on risk of bias assessment is provided in the Appendix.
Data synthesis
The Revman software package (The Nordic Cochrane Centre (The Cochrane Collab-
oration), 2014) was used to perform a series of meta-analyses for continuous and
dichotomous outcome measures. A random effects model was used to account for
participants coming from different underlying populations. We used the transforma-
tions as laid down by the Cochrane Handbook (Higgins and Green, 2011) for contin-
uous outcomes. For conversions of standard error into standard deviations and the
calculation of standard deviations calculated from 95% confidence intervals (CIs) we
used the standard equations set out in Fig. 1.
Economic appraisal
Economic or resource use information was assessed using the Drummond classification
scheme (see Appendix) (Drummond et al., 2005). This criterion was applied by an
economist to indicate the costs and the consequences of the intervention(s) relevant to
various public sectors. These included healthcare, criminality, labour force participation
or other public goods. According to Drummond, studies containing information on the
economics of the intervention can be classified as full economic evaluation studies or
partial economic evaluation studies (Drummond et al., 2005). A full economic evalu-
ation is a comparative analysis of two or more interventions in terms of both resource
Fig. 1 Statistical treatment
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use (or costs) and outcomes (or consequences) (Drummond et al., 2005). Full economic
evaluations can be further classified as cost-benefit analysis, cost-effectiveness analysis
and cost-utility analysis based on consequences measured in monetary units, physical
units (e.g. mortality) and utilities (e.g. quality-adjusted life years (QALYs)), respec-
tively. Evaluations that are not comparative or do not consider both costs and conse-
quences are classified as partial evaluations (e.g. cost-outcome description or cost
analysis). Studies containing economic information using the Drummond criteria were
identified, and information related to resource use and perspectives were recorded.
Search results
Searches for this review were first conducted in Perry (Perry et al., 2006, Perry et al.,
2015) and were last updated in February 2019. The searches identified a total of 16,786
records and 988 additional records were identified from other sources. Following
deduplication, 9657 records were screened using information in the title and abstract.
Of these, 9406 records were excluded. We acquired the remaining 251 full papers for
assessment and excluded 237 of these. A total of 22 studies were finally deemed
eligible for the review and were included in the qualitative synthesis, with 19 of them
included in the meta-analyses. The 22 included studies randomised 4372 participants
from research published between 1969 and 2019. Fig. 2 shows the PRISMA flow
diagram of the numbers of records included and excluded at each stage of the selection
process.
Fourteen of the 22 trials were conducted in the US and three in the UK. The other 5
studies were conducted in Iran, Australia, Norway, Sweden and Mexico. Twenty-one
of the 22 studies included male adult drug-using offenders and 1 study recruited only
female participants (Cropsey et al., 2011). In 2 studies, the percentage of each gender
was not reported (Kurland et al., 1975, Wright et al., 2011).
The age of study participants ranged from 17 to 55 years. In 7/22 (32%) studies, the
majority of participants were of white ethnic origin. The studies were divided by setting
into community (n = 9) (Brodie et al., 2009, Brown et al., 2013, Cornish et al., 1997,
Coviello et al., 2010, Cropsey et al., 2011, Hanlon et al., 1975, Hanlon et al., 1977,
Kurland et al., 1975, Lee et al., 2016), prison (n = 7) (Bayanzadeh, 2004, Dolan et al.,
2003, Dole et al., 1969, Howells et al., 2002, Lobmaier et al., 2010, Rich et al., 2015,
Wright et al., 2011) and those that started in a secure setting and continued into the
community (n = 6) (Kinlock et al., 2005, Kinlock et al., 2007, Konstenius et al., 2014,
Magura et al., 2009, McKenzie et al., 2012, Parmar et al., 2017).
Fifteen of the 22 trials evaluated outcomes at 6 months or less, 4 trials reported
outcomes up to 12 months (Brown et al., 2013, Dole et al., 1969, Kinlock et al., 2007),
1 study reported outcomes at 18 months (Lee et al., 2015) and 1 reported outcomes at
4 years (Dolan et al., 2003).
Different outcome measures were presented for each study, and just over half of all
studies reported 4 or more outcome measures. One study reported on criminal activity
only (Cornish et al., 1997) and 8 trials reported on drug use only (Bayanzadeh, 2004,
Brown et al., 2013, Cropsey et al., 2011, Dolan et al., 2003, Hanlon et al., 1977,
Konstenius et al., 2014, Wright et al., 2011). Six studies did not report any information
on adverse events, side effects from the drug or drug safety (Bayanzadeh, 2004, Dolan
et al., 2003, Dole et al., 1969, Hanlon et al., 1975, Hanlon et al., 1977, Kurland et al.,
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1975). Three studies referred to the measurement of adverse events but did not report
them (Coviello et al., 2010, Cropsey et al., 2011, Wright et al., 2011). 4 studies reported
resource and cost information (Magura et al., 2009, Murphy et al., 2017, Rich et al.,
2015, Warren et al., 2006).
Overview of studies
Meta-analyses
Nineteen of the 22 studies provided data to potentially be included in 1 or more meta-
analyses. The interventions report on agonistic pharmacological interventions
(buprenorphine, methadone) and antagonistic pharmacological interventions (naltrex-
one and naloxone) compared with no intervention, other non-pharmacological treat-
ments (e.g. counselling) and other pharmacological drugs (vigabatrin and cyclazocine).
The comparisons are shown in Table 3 and in Fig. 3.
Agonist (methadone) versus no intervention (placebo or waiting list control)
Two studies (237 participants) (Cropsey et al., 2011, Dolan et al., 2003) showed no
significant reduction in drug use using biological measures (RR 0.74, 95% CI 0.53 to
Fig. 2 PRISMA flow diagram
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95% CI P value
Agonist (methadone) vs no intervention (placebo or waiting list control)
Drug use (objective) Cropsey et al. 2011
Dolan et al. 2003
237 RR: 0.72 0.51, 1.00 0.05
Self-reported drug use
(dichotomous)
Cropsey et al. 2011
Dolan et al. 2003
Dole et al. 1969
317 RR: 0.61 0.31, 1.18 0.14
Self-reported drug use
(continuous)
Dolan et al. 2003
Kinlock et al. 2005
459 SMD: − 0.64 − 0.90, − 0.39 < 0.0001
Criminal activity—arrests
(dichotomous)




Dolan et al. 2003
Dole et al. 1969
Kinlock et al. 2005
472 RR: 0.77 0.36, 1.64 0.50
Criminal activity
(continuous)
Kinlock et al. 2005 51 MD: − 74.21 − 133.53, 14.89 0.01
Agonist (methadone) vs partial agonist (buprenorphine)
Self-reported drug use
(dichotomous)
Magura et al. 2009
Wright 2001
370 RR: 1.04 0.69, 1.55 0.87
Self-reported drug use
(continuous)




Magura et al. 2009 116 RR: 1.25 0.83, 1.88 0.28
















44 MD: − 0.50 − 8.04, 7.04 0.90




Kinlock et al. 2007
203 RR: 0.39 0.14, 1.13 0.08
Agonist (vigabatrin) vs placebo
Number of negative urine
tests for cocaine
Brodie et al. 2009 103 MD 2.10 − 0.34, 4.54 0.09
End of trial abstinence for
cocaine
Brodie et al. 2009 103 RR: 1.06 0.28, 4.01 0.93
End of trial abstinence for
marijuana
Brodie et al. 2009 103 RR: 0.64 0.16, 2.52 0.52
Antagonist (naloxone) vs no intervention (placebo or waiting list control)
Self-reported drug use Kurland et al. 1975
Parmer 2016
Hanlon et al. 1977
333 RR: 1.02 0.89, 1.16 0.78











95% CI P value




Cornish et al. 1997
Coviello et al. 2010
Lee et al. 2016
422 RR: 0.55 0.31, 0.99 0.05
Criminal activity—drugs
charges (dichotomous)
Coviello et al. 2010 63 RR: 3.10 0.34, 28.19 0.32
Drug use (objective)—
opioids
Coviello et al. 2010
Lee et al. 2016
371 RR: 0.60 0.44, 0.81 0.0
Drug use (objective)—
cocaine
Coviello et al. 2010
Lee et al. 2016
391 RR: 1.47 0.67, 3.23 0.33
Mixed antagonist and agonist (cyclazocine) vs antagonist (naloxone)
Abstinent at 6 months Hanlon et al. 1975 70 RR: 1.14 0.46, 2.81 0.77
Agonist (methadone) vs forced tapered withdrawal from methadone
Drug use and reincarceration
1 month post release
Rich et al. 2015 1078 RR: 0.86 0.63, 1.17 0.23
Any other drug use at
1 month post release
Rich et al. 2015 283 RR: 1.05 0.83, 1.34 0.68
Reincarceration at 1 month
post release
Rich et al. 2015 229 RR: 0.92 0.39, 2.16 0.85
Opioid use at 1 month post
release
Rich et al. 2015 283 RR: 0.56 0.26, 1.22 0.14
Use of injectable illegal drug Rich et al. 2015 283 RR: 0.67 0.40, 1.15 0.15
Agonist (methadone) prior to release with financial support vs agonist (methadone) on release with no
financial support




61 RR: 0.53 0.22, 1.25 0.14





61 RR: 0.14 0.01, 2.57 0.18





61 RR: 0.53 0.22, 1.25 0.14




61 RR: 0.48 0.10, 2.45 0.38




61 RR: 0.81 0.41, 1.58 0.53




61 RR: 0.36 0.11, 1.24 0.11
Criminal justice outcomes McKenzie et al.
2012





61 RR: 0.48 0.10, 2.45 0.38
Arrested in past 6 months McKenzie et al.
2012
61 RR: 1.45 0.59, 3.58 0.42
CI confidence interval, RR risk ratio, SMD standardised mean difference, MD mean difference
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1.02) and three studies (317 participants) showed no significant reduction in self-
reported drug use (RR 0.61, 95% CI 0.31 to 1.18) (Cropsey et al., 2011, Dolan et al.,
2003, Dole et al., 1969). Two studies (304 participants) showed a significant reduction
in self-reported drug use (SMD − 0.57, 95% CI − 0.80 to − 0.34) (Dolan et al., 2003,
Kinlock et al., 2005). For criminal activity, one study (62 participants) showed no
significant reduction in re-arrests (RR 0.60, 95% CI 0.32 to 1.14) (Kinlock et al., 2005).
Three studies (472 participants) showed no significant reduction in reincarceration (RR
0.77, 95% CI 0.36 to 1.64) (Dolan et al., 2003, Dole et al., 1969, Kinlock et al., 2005)
and one study (51 participants) showed a significant reduction in criminal activity (MD
− 74.21, 95% CI − 133.53 to − 14.89) (Kinlock et al., 2005).
Agonist (methadone) versus partial agonist (buprenorphine)
Two studies (370 participants) showed no significant reduction in self-reported drug
use (RR 1.04, 95% CI 0.69 to 1.55) (Magura et al., 2009, Wright et al., 2011). One
study (81 participants) showed no significant reduction in self-reported drug use (MD
0.70, 95% CI − 5.33 to 6.73) (Magura et al., 2009). One study (116 participants)
showed no significant reduction in criminal activity (RR 1.25, 95% CI 0.83 to 1.88)
(Magura et al., 2009).
Agonist (methadone) versus antagonist (naltrexone)
A single study (44 participants) showed no significant reduction in self-reported drug
use (MD 4.60, 95% CI − 3.54 to 12.74) and showed no significant reduction in
dichotomous (RR 1.10, 95% CI 0.37 to 3.26) or continuous measures of reincarceration
(MD − 0.50, 95% CI − 8.04 to 7.04) (Lobmaier et al., 2010).
Agonist (methadone) and non-pharmacological intervention versus
non-pharmacological intervention
Two studies (203 participants) showed no significant reduction in self-reported drug
use (RR 0.39, 95% CI 0.14 to 1.13) (Bayanzadeh, 2004, Kinlock et al., 2007).
Agonist (vigabatrin) versus placebo
One study (103 participants) showed no evidence of a difference in terms of the number
of negative urine tests for cocaine (MD 2.1, 95% CI − 0.34 to 4.54) and end of trial
abstinence for marijuana (RR 0.64, 95% CI 0.16 to 2.52) but showed evidence of a
difference in the end of trial abstinence (RR 1.06, 95% CI 0.28 to 4.01) and 4-week
abstinence for cocaine (RR 6.36, 95% CI 1.50 to 27.01) (Bayanzadeh, 2004, Brodie
et al., 2009, Kinlock et al., 2007).
Antagonist (naloxone) versus no intervention (placebo or waiting list control)
Three studies (333 participants) showed no significant reduction in self-reported drug
use (RR 1.06, 95% CI 0.87 to 1.28) (Hanlon et al., 1975, Hanlon et al., 1977, Parmar
et al., 2017).
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Antagonist (naltrexone) versus non-pharmacological treatment
Two studies (371 participants) showed a significant reduction in subsequent opioid use
(RR 0.60, 95% CI 0.44 to 0.81) (Coviello et al., 2010, Lee et al., 2016). Two studies
Drug use (objecve)
Self-reported drug use (dichotomous)
Self-reported drug use (connuous)
Criminal acvity – reincarnaon (dichotomous)
Self-reported drug use (dichotomous)




Fig. 3 Forest plots of intervention effects
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(371 participants) showed no significant reduction in cocaine use (RR 1.24, 95% CI
0.54 to 2.84) (Coviello et al., 2010, Lee et al., 2016). Three studies (422 participants)
showed a significant reduction in subsequent reincarceration (RR 0.55, 95% CI 0.31 to
0.99) (Cornish et al., 1997, Coviello et al., 2010, Lee et al., 2016). One study (63
participants) showed no significant reduction in subsequent drug charges (RR 3.10,
95% CI 0.34 to 28.19) (Coviello et al., 2010).
Mixed antagonist and agonist (cyclazocine) versus antagonist (naloxone)
One study (70 participants) showed no significant reduction in abstinence at 6 months
comparing mixed antagonist and agonist (cyclazocine) with the antagonist naloxone
(RR 1.14, 95% CI 0.46 to 2.81) (Hanlon et al., 1975).
Self-reported drug use
Criminal acvity – reincarnaon (dichotomous)
Drug use (objecve) – opioids
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Agonist (methadone) versus forced tapered withdrawal from methadone
One study (283 participants) explored continued use of methadone within a prison
setting compared with forced tapered withdrawal of methadone (Rich et al., 2015). The
study found no significant difference in reduction in any drug use at 1 month following
release from prison (RR 1.05, 95% CI 0.83 to 1.34), opioid use at 1 month following
release (RR 0.56, 95% CI 0.26 to 1.22) or use of injectable illegal drugs (RR 0.67, 95%
CI 0.40 to 1.15) (Rich et al., 2015). The study also found no difference between the two
options in terms of reincarceration at 1 month post release from prison (RR 1.49, 95%
CI 0.63 to 3.53) (Rich et al., 2015).
Agonist (methadone) prior to release with financial support versus agonist
(methadone) on release with no financial support
One study (46 participants) explored the impact of providing financial support for
methadone treatment following release from prison compared with no financial support
on drug outcomes and criminal justice outcomes (McKenzie et al., 2012). The study
found no significant difference between the two options in terms of heroin use in the
past 30 days (RR 0.46, 96% CI 0.20 to 1.03), use of other opiates in the past 30 days
(RR 0.12, 95% CI 0.01 to 2.22), use of crack/cocaine in the past 30 days (RR 0.46,
95% CI 0.20 to 1.03), marijuana use in the past 30 days (RR 0.42, 95% CI 0.09 to
2.07), polydrug use in the past 30 days (RR 0.70, 95% CI 0.38 to 1.28) or any drug
injecting in the past 30 days (RR 0.32, 95% CI 0.10 to 1.04) (McKenzie et al., 2012).
The study reported no significant difference between the interventions for
reincarceration (RR 0.42, 95% CI 0.09, 2.07) or arrest within the past 6 months (RR
1.26, 95% CI 0.54, 2.96) (McKenzie et al., 2012).
Narrative findings
Narrative findings were presented for three studies where suitable data for extraction
and exclusion in the meta-analysis were not available. One study compared methyl-
phenidate or placebo to a non-pharmacological intervention (Konstenius et al., 2014).
In this study, male participants with attention deficit disorder receiving methylpheni-
date had a higher proportion of drug negative urine test results compared with the
placebo group (p = 0.047). A second study compared a specialist facility for treatment
of methadone versus primary care plus suboxone (buprenorphine and naloxone) versus
a specialist facility for suboxone treatment (Brown et al., 2013). At 6 months, the
authors reported no use of opioids in any of the randomised groups (total of 15
participants). The final study compared methadone and placebo versus lofexidine and
placebo (Howells et al., 2002). The authors reported no statistical reduction in the
amount (p = 0.36) or intensity (p = 0.46) of opioid (heroin) use in the last month.
Adverse events
Seven of the 22 (32%) studies did not report any information on adverse events, side
effects of drugs nor referred to drug safety (Bayanzadeh, 2004, Brown et al., 2013,
Dolan et al., 2003, Dole et al., 1969, Hanlon et al., 1975, Hanlon et al., 1977, Kurland
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et al., 1975). Three (3/22, 14%) studies measured adverse events, but did not report the
findings (Coviello et al., 2010, Cropsey et al., 2011, Wright et al., 2011). Forty-one
percent of the studies (9/22) reported only mild or moderate adverse events (Brodie
et al., 2009, Cornish et al., 1997, Howells et al., 2002, Kinlock et al., 2005, Konstenius
et al., 2014, Lee et al., 2016, Lobmaier et al., 2010, Magura et al., 2009, Parmar et al.,
2017). One study reported 10 serious adverse events including nine hospitalisations
(Kinlock et al., 2007). The hospitalisations included two cases for heart disease and one
each for pneumonia, alcohol detoxification, kidney disease, high blood pressure,
psychiatric problems and back pain (Kinlock et al., 2007). Two studies reported a fatal
overdose (Kinlock et al., 2007, Rich et al., 2015) and one study reported two fatal
overdoses (McKenzie et al., 2012).
Economic outcomes
The economic appraisal using the Drummond criteria identified four studies reporting
some cost information (Magura et al., 2009, Murphy et al., 2017, Rich et al., 2015,
Warren et al., 2006). Table 4 shows the results of the type of resource costs described
for each paper. Three of the four studies were full economic evaluations reporting both
incremental costs and outcomes (Magura et al., 2009, Murphy et al., 2017, Warren
et al., 2006).
In terms of the overall Drummond classification (Drummond et al., 2005), three
studies were coded as 4 (a full economic evaluation) and one study was coded as 3
(partial economic evaluation).
The Magura 2009 (Magura et al., 2009) study noted differences in the costs of
administering buprenorphine and methadone, but were not sufficient for us to conduct a
full cost-effectiveness appraisal. The investigators estimated that about ten times as
many inmates can be served with methadone as with buprenorphine with the same staff
resources. This cost implication is also endorsed in the community, where physicians
have difficulty in obtaining reimbursement for buprenorphine treatment for released
inmates, making the continued use of buprenorphine problematic after release.
The Murphy 2017 (Murphy et al., 2017) study conducted a full economic analysis
reporting incremental cost-effectiveness ratios (ICERs), costs, QALYs and abstinent
years of using extended-release naltrexone (XR-NTX) compared with treatment as
usual (TAU) at 25 weeks and 78 weeks, respectively. The 25-week ICERs were
reported as $162,150/QALY and $46,329/ abstinent year. The ICER values at 78 weeks
were $76,400/QALY and $16,371/abstinent year. The study reported that XR-NTX
was effective in increasing both QALYs and abstinence rates compared with TAU.
However, it was not cost-effective at the normally accepted threshold levels in the US,
primarily due to the high price of the injection.
The Warren 2006 (Warren et al., 2006) study estimated the cost-effectiveness of the
New South Wales (NSW) prison methadone programme compared with no methadone
program. The study reported the annual cost of providing prison methadone in NSW as
AUD$2.9million (or AUD$3234 per inmate per year) and the ICER as AUD $38 per
additional heroin-free day. It also reported that prison methadone is not costlier than
community methadone, and it reduces morbidity and mortality through decreasing
heroin use in prisons.
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Table 4 Available economic information (resource use and/or cost) and evaluation type according to Drummond classification scheme (see Appendix)
Study Sample description Location/
country
Perspective Intervention Does the study describe resource use and/or costs for Drummond score





Inmates aged 18–65 years eligible for Key













Participants aged 18–60 years diagnosed with
opioid dependence and serving an
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The final study by Rich 2015 (Rich et al., 2015) reported, as a secondary outcome,
on healthcare costs (per inmate) associated with continued methadone maintenance-
treatment programme compared with usual care (i.e. forced withdrawal from metha-
done) at 1 month after release from incarceration. Continued methadone treatment
resulted in higher (methadone) treatment cost per individual compared with forced
withdrawal ($362 vs $225, p < 0.001). The additional treatment costs were offset by
savings incurred by reduced cost for physician ($6.60 vs $8.80, p = 0.793) and medical
care ($211 vs $372, p = 0.894) after release, resulting in lower total costs ($609 vs
$637, p < 0.001). Continued methadone treatment also resulted in a greater probability
of attendance at a methadone clinic after release and was more effective than forced
withdrawal.
Risk of bias assessment
Although all the included studies were randomised trials, the level of reporting was
uneven and many had unclear or high risk of bias for at least one element of the risk of
bias assessment. Nearly 50% were rated as unclear risk of bias in terms of random
sequence generation and over 50% of the trials were rated as unclear in terms of
allocation concealment. 32% (7/22) of the studies were rated as low risk of bias for
participant and personnel blinding and 82% (18/22) were rated as unclear on both
subjective and objective measures of detection bias. Over 75% of the trials were at high
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Blinding of outcome (objecve outcomes)
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Low risk of bias 11 5 7 7 1 0 3 12
Unclear risk of bias 10 12 7 7 19 21 18 6
High risk of bias 1 5 8 8 2 1 1 4
Risk of bias graph: judgements about each risk of bias item are 
presented as percentages across all included studies.
Low risk of bias Unclear risk of bias High risk of bias
Fig. 4 Risk of bias judgements
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Over 50% of the studies were rated at low risk for selective reporting. The overall risk
of bias judgements of the included studies are shown in Fig. 4, and summary and
detailed accounts of the risk of bias assessment can be found in the Appendix.
Conclusions
The results of this systematic review provide some evidence to answer our original
review questions. The review identified that we have some evidence to suggest that
pharmacological interventions are effective in reducing drug use and criminal activity
(Perry et al., 2015). The updated review revealed a total of 22 trials involving 4372
participants. The 22 trials compared pharmacological interventions or compared phar-
macological interventions to no intervention and/or a placebo. Most studies were
conducted in the USA, with the majority involving male adult offenders. The updated
meta-analyses included 19/22 quantitative studies. Ten different pharmacological drugs
were evaluated including methadone, buprenorphine, naltrexone, methylphenidate,
vigabatrin, suboxone, naloxone, lofexifine, naltrexone and cyclazocine. Methadone in
comparison with no treatment was the only comparison to demonstrate a significant
reduction in subsequent drug use (using biological measures), self-reported drug use
(using continuous measures) and criminal activity. When compared with methadone,
no significant differences were found for buprenorphine, naltrexone or suboxone. None
of these studies identified a significant reduction in either criminal activity and/or drug
use. One study comparing buprenorphine to placebo (Cropsey et al., 2011) was the
only study to involve wholly female offenders. More pharmacological trials of female
offenders are required to identify comparability between men and women.
Studies of naloxone and methylphenidate in comparison with a placebo and non-
pharmacological intervention, respectively, showed no significant differences for self-
reported drug use. The evidence supporting the use of naloxone was explored using
two very old studies (Hanlon et al., 1977, Hanlon et al., 1975) and one more recent
study that had to be halted early due to problems with the randomisation procedure
(Parmar et al., 2017). Naltrexone in comparison with a non-pharmacological interven-
tion showed a significant reduction in self-reported drug use and reincarceration. The
use of extended naltrexone pre and post prison release has produced some promising
results, finding no overdoses during the treatment process (Lee et al., 2016). This study
also reported that use of extended-release naltrexone was associated with a rate of
opioid relapse that was lower than that with usual treatment at 24 weeks, but later
comparisons (at 52 and 78 weeks) found no difference between the use of extended-
release naltrexone and use of a brief counselling intervention (Lee et al., 2016). One
study investigated methadone continuation treatment compared with forced tapered
withdrawal from methadone within a prison setting, but found no significant difference
in the reduction of any drug use at 1 month following release (Rich et al., 2015). The
study also found no difference between the treatment options where reincarceration
occurred at 1 month post release from prison. The impact of providing financial support
for methadone treatment following release from prison was compared with no financial
support in one study, but no significant difference was observed in terms of drug use or
criminal justice outcomes (McKenzie et al., 2012). The study also reported no signif-
icant difference between the interventions in relation to arrest or reincarceration at six-
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month follow-up. We were unable to answer our third review questions about the
impact of treatment setting on drug use or criminal activity. This was primarily because
of the heterogeneity of the study comparisons and outcome measures. Given the
relatively scarce resources for drug treatment evaluation opportunities in this popula-
tion, future research should seek to build on existing trial data to develop an evidence-
base to allow for such comparisons to be made.
The majority of studies included in the review reported only mild to moderate
adverse effects, or did not report on drug safety as part of the trial information. One
study reported serious adverse effects and three studies reported overdoses. Adverse
effects should be measured consistently across any pharmacological drug trial to
capture important data about drug safety. The current evidence does not provide a
comprehensive overview of drug safety within this population.
Our final review question focused on the comparative costs and cost-effectiveness
evidence of using such interventions to reduce drug use and criminal activity. An
appraisal of the economic evidence identified studies with costs and outcomes data for
pharmacological treatments among drug-using offenders in three studies and costs data
in one study. All studies reported data on the direct medical costs associated with the
provision of treatment (Magura et al., 2009, Murphy et al., 2017, Rich et al., 2015,
Warren et al., 2006) and one study also included costs related to criminal justice
(Murphy et al., 2017). The findings from the studies revealed the higher effectiveness
of pharmacological treatments in terms of increased QALYs and abstinent years
(Murphy et al., 2017) and reduced heroin use (Warren et al., 2006). One study reported
methadone to be cost-effective at the current willingness to pay thresholds (Warren
et al., 2006). Another study reported continued methadone treatment to dominate
forced withdrawal in terms of costs and effects (Rich et al., 2015). More research is
needed to compare the relative cost-effectiveness of a range of treatments (pharmaco-
therapies, non-pharmacological interventions and combined treatments) in prison and
community-based criminal justice settings.
Additionally, the studies contained mainly male offenders, with only one study
containing a 100% sample of female offenders. The majority of studies were conducted
in the USA. Together these factors limit the external validity and generalisability of the
study findings. For these reasons, the studies are unlikely to reflect different interna-
tional practice in the criminal justice system. Besides the limitations already discussed,
the search methodology was limited to databases that could be accessed via the
University of York and extensive website searches were not conducted. As a result,
some literature may have been missed from this updated version. Specific search terms
were not used to identify cost and cost-effectiveness studies in 3/12 databases which
meant that some economic studies might have been missed from this review.
Several research implications can be identified from this review. Generally, better
quality research is required to evaluate the effectiveness of interventions with extended
long-term effects of aftercare following release into the community. Buprenorphine
research in the prison environment requires evidence of the long-term impact and larger
studies; currently, an equivalence of buprenorphine and methadone exists. Future
clinical trials should collect information from all sectors of the criminal justice system.
This would enhance the heterogeneous nature of the included studies and would
facilitate generalisation of study findings. Evidence of comparable mortality rates in
prisoners using pharmacological interventions (particularly after release) needs to be
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explored to assess the long-term outcomes of such treatments, perhaps using alternative
study designs to randomised controlled trials. The link between dosage, treatment
retention and subsequent criminal activity should be examined across all three phar-
macological treatment options. Evidence from other trial data suggests that dose has
important implications for retention in treatment; in future studies, this should be
considered alongside criminal activity outcomes. Cost and cost-effectiveness informa-
tion should be standardised within trial evaluations; this will help policymakers to
decide upon health versus criminal justice costs.
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Appendix
1. Search Strategy
The searches for this updated review were conducted in February 2019 in the following
databases:
ASSIA, CENTRAL, CINAHL, Criminal Justice Abstracts, Embase, HMIC, LI-
LACS, MEDLINE, PAIS, PsycINFO, Science Citation Index, Social Science Citation
Index.
Initially, there were 4384 records identified. After deduplication, there were 2603
records remaining. After further deduplication against the results of the January 2018
update search, 2445 records remained.
1.1 ASSIA search strategy
ASSIA via ProQuest search strategy (search date = 6th February 2019, 247 records identified)
(ti(substance* NEAR/2 (addict* OR depend* OR disorder* OR abuse* OR abusing ORmisuse* ORmisusing
OR consumption* OR withdraw* OR withdraw* OR detox*)) OR ab(substance* NEAR/2 (addict* OR
depend* OR disorder* OR abuse* OR abusing OR misuse* OR misusing OR consumption* OR
withdraw* OR withdraw* OR detox*)) OR ti(drug* NEAR/2 (addict* OR depend* OR disorder* OR
abuse* OR abusing OR misuse* OR misusing OR consumption* OR withdraw* OR withdraw* OR
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detox*)) OR ab(drug* NEAR/2 (addict* OR depend* OR disorder* OR abuse* OR abusing OR misuse*
OR misusing OR consumption* OR withdraw* OR withdraw* OR detox*)) OR ti(narcotic* NEAR/2
(addict* OR depend* OR disorder* OR abuse* OR abusing OR misuse* OR misusing OR consumption*
OR withdraw* OR withdraw* OR detox*)) OR ab(narcotic* NEAR/2 (addict* OR depend* OR disorder*
OR abuse* OR abusing OR misuse* OR misusing OR consumption* OR withdraw* OR withdraw* OR
detox*)) OR ti(mdma OR alcohol* OR opiate* OR opioid* OR opium OR heroin OR methadone OR
cocaine OR amphetamine* OR marijuana OR cannabis OR crack OR phencyclidine) OR ab(mdma OR
alcohol* OR opiate* OR opioid* OR opium OR heroin OR methadone OR cocaine OR amphetamine* OR
marijuana OR cannabis OR crack OR phencyclidine)) AND (ti((justice system) OR remand* OR parole*
OR probation OR court* OR corrections OR correctional OR revocation) OR ab((justice system) OR
remand* OR parole* OR probation OR court* OR corrections OR correctional OR revocation) OR ti(crime
OR offend* OR criminal OR convict* OR felon*) OR ab(crime OR offend* OR criminal* OR convict*
OR felon*) OR ti(custody OR custodial OR gaol* OR jail* OR prison* OR incarcerat* OR inmate*) OR
ab(custody OR custodial OR gaol* OR jail* OR prison* OR incarcerat*or inmate*) OR ti(reoffend* OR
reincarcerat* OR recidiv* OR ex-offender*) OR ab(reoffend* OR reincarcerat* OR recidiv* OR
ex-offender*)) AND pd(20180101-20190201)
1.2 The CENTRAL Register of Controlled Trials search strategy
CENTRAL via Cochrane Library search strategy (search date = 6th February 2019, 78 records
identified)
#1MeSH descriptor: [Substance-Related Disorders] explode all trees
#2MeSH descriptor: [Illicit Drugs] explode all trees
#3MeSH descriptor: [Designer Drugs] explode all trees
#4MeSH descriptor: [Narcotics] explode all trees
#5(substance* or drug* or narcotic*) near/2 (addict* or depend* or disorder* or abuse* or abusing or misuse*
or misusing or consumption* or withdraw$ or withdraw* or detox*):ti,ab,kw (Word variations have been
searched)
#6mdma or alcohol* or opiate* or opioid* or opium or heroin or methadone or cocaine or amphetamine* or
marijuana or cannabis or crack or phencyclidine:ti,ab,kw (Word variations have been searched)
#7#1 or #2 or #3 or #4 or #5 or #6
#8MeSH descriptor: [Crime] explode all trees
#9MeSH descriptor: [Criminals] explode all trees
#10MeSH descriptor: [Prisoners] explode all trees
#11(justice system) or remand* or parole* or probation or court* or corrections or correctional or
revocation:ti,ab,kw (Word variations have been searched)
#12custody or custodial or gaol* or jail* or prison* or incarcerat* or inmate*:ti,ab,kw (Word variations have
been searched)
#13reoffend* or reincarcerat* or recidiv* or ex-offender*:ti,ab,kw (Word variations have been searched)
#14offend* or criminal* or convict* or felon:ti,ab,kw (Word variations have been searched)
#15#8 or #9 or #10 or #11 or #12 or #13 or #14
#16#7 and #15
1.3 CINHAL Plus search strategy
CINHAL Plus via EBSCO search strategy (search date = 6th February 2019, 774 records identified)
S1
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TI (substance* N2 (addict* or depend* or disorder* or abuse* or abusing or misuse* or misusing or
consumption* or withdraw* or withdraw* or detox*)) OR AB (substance* N2 (addict* or depend* or
disorder* or abuse* or abusing or misuse* or misusing or consumption* or withdraw* or withdraw* or
detox*)) OR TI (drug* N2 (addict* or depend* or disorder* or abuse* or abusing or misuse* or
misusing or consumption* or withdraw* or withdraw* or detox*)) OR AB (drug* N2 (addict* or
depend* or disorder* or abuse* or abusing or misuse* or misusing or consumption* or withdraw* or
withdraw* or detox*)) OR TI (narcotic* N2 (addict* or depend* or disorder* or abuse* or abusing or
misuse* or misusing or consumption* or withdraw* or withdraw* or detox*)) OR AB (narcotic* N2
(addict* or depend* or disorder* or abuse* or abusing or misuse* or misusing or consumption* or
withdraw* or withdraw* or detox*))
S2 TI (mdma or alcohol* or opiate* or opioid* or opium or heroin or methadone or cocaine or
amphetamine* or marijuana or cannabis or crack or phencyclidine) OR AB (mdma or alcohol* or
opiate* or opioid* or opium or heroin or methadone or cocaine or amphetamine* or marijuana or
cannabis or crack or phencyclidine)
S3 S1 OR S2
S4 TI (justice system) or crime or remand* or parole* or probation or court* or corrections or correctional or
revocation) OR AB (justice system) or crime or remand* or parole* or probation or court* or
corrections or correctional or revocation) OR TI (offend* or criminal* or convict* or felon*) OR AB
(offend* or criminal* or convict* or felon*) OR TI (custody or custodial or gaol* or jail* or prison* or
incarcerat* or inmate*) OR AB (custody or custodial or gaol* or jail* or prison* or incarcerat* or
inmate*) OR TI (reoffend* or reincarcerat* or recidiv* or ex-offender*) OR AB (reoffend* or
reincarcerat* or recidiv* or ex-offender*)
S5 S3 AND S4
1.4 Criminal Justice Abstracts search strategy
Criminal justice abstracts via ProQuest search strategy (search date = 6th February 2019, 594 records)
S1 ab(reoffend* OR reincarcerat* OR recidiv* OR ex-offender*))
S2 ti(reoffend* OR reincarcerat* OR recidiv* OR ex-offender*) OR
S3 ab(custody OR custodial OR gaol* OR jail* OR prison* OR incarcerat*or inmate*) OR
S4 ti(custody OR custodial OR gaol* OR jail* OR prison* OR incarcerat* OR inmate*) OR
S5 ab(crime OR offend* OR criminal* OR convict* OR felon*) OR
S6 ti(crime OR offend* OR criminal OR convict* OR felon*) OR
S7 ab((justice system) OR remand* OR parole* OR probation OR court* OR corrections OR correctional
OR revocation) OR
S8 (ti((justice system) OR remand* OR parole* OR probation OR court* OR corrections OR correctional
OR revocation) OR
S9 s1 or s2 or s3 or s4 or s5 or s6 or s7 or s8
S10 ab(mdma OR alcohol* OR opiate* OR opioid* OR opium OR heroin OR methadone OR cocaine OR
amphetamine* OR marijuana OR cannabis OR crack OR phencyclidine))
S11 ti(mdma OR alcohol* OR opiate* OR opioid* OR opium OR heroin OR methadone OR cocaine OR
amphetamine* OR marijuana OR cannabis OR crack OR phencyclidine) OR
S12 ab(narcotic* NEAR/2 (addict* OR depend* OR disorder* OR abuse* OR abusing OR misuse* OR
misusing OR consumption* OR withdraw* OR withdraw* OR detox*)) OR
S13 ti(narcotic* NEAR/2 (addict* OR depend* OR disorder* OR abuse* OR abusing OR misuse* OR
misusing OR consumption* OR withdraw* OR withdraw* OR detox*)) OR
S14
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ab(drug* NEAR/2 (addict* OR depend* OR disorder* OR abuse* OR abusing OR misuse* OR
misusing OR consumption* OR withdraw* OR withdraw* OR detox*)) OR
S15 ti(drug* NEAR/2 (addict* OR depend* OR disorder* OR abuse* OR abusing ORmisuse* ORmisusing
OR consumption* OR withdraw* OR withdraw* OR detox*)) OR
S16 ab(substance* NEAR/2 (addict* OR depend* OR disorder* OR abuse* OR abusing OR misuse* OR
misusing OR consumption* OR withdraw* OR withdraw* OR detox*)) OR
S17 (ti(substance* NEAR/2 (addict* OR depend* OR disorder* OR abuse* OR abusing OR misuse* OR
misusing OR consumption* OR withdraw* OR withdraw* OR detox*)) OR
S18 s10 or s11 or s12 or s13 or s14 or s15 or s16 or s17
S19 s9 and s18
1.5 EMBASE via Ovid search strategy
Embase via Ovid search strategy (search date = 6th February 2019, 213 records
Database: Embase <2015 to 2019 Week 05)
1 substance abuse/ (9875)
2 drug dependence/ (11329)
3 addiction/ (6500)
4 drug abuse/ (6705)
5 intravenous drug abuse/ (1611)
6 opiate addiction/ (5462)
7 heroin dependence/ (1491)
8 cocaine dependence/ (2564)
9 morphine addiction/ (586)
10 cannabis addiction/ (2161)
11 alcoholism/ (18489)
12 alcohol abuse/ (6835)
13 ((substance$ or drug$ or narcotic$) adj2 (addict$ or depend$ or disorder$ or abuse$ or abusing or misuse$
or misusing or consumption$ or withdraw$ or withdraw$ or detox$)).ti,ab. (29221)
14 (mdma or alcohol$ or opiate$ or opioid$ or opium or heroin or methadone or cocaine or amphetamine$ or
marijuana or cannabis or crack or phencyclidine).ti,ab. (146170)
15 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 (179011)
16 exp. crime/ (13956)
17 criminal behavior/ (1234)
18 criminal justice/ (1360)
19 prisoner/ or offender/ (6567)
20 (justice system or remand$ or parole$ or probation or court$ or corrections or correctional or
revocation).ti,ab. (13647)
21 (offend$ or criminal$ or convict$ or felon$).ti,ab. (10272)
22 (custody or custodial or gaol$ or jail$ or prison$ or incarcerat$ or inmate$).ti,ab. (8080)
23 (reoffend$ or reincarcerat$ or recidiv$ or ex-offender$).ti,ab. (1723)
24 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 (40493)
25 clinical trial/ (128414)
26 randomised controlled trial/ (169099)
27 randomisation/ (15096)
28 single blind procedure/ (14215)
29 double blind procedure/ (38131)
30 crossover procedure/ (15966)
31 placebo/ (71036)
32 randomi?ed. controlled trial$.tw. (84975)
33 rct.tw. (14740)
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34 random allocation.tw. (482)
35 randomly allocated.tw. (9673)
36 allocated randomly.tw. (397)
37 (allocated adj2 random).tw. (83)
38 single blind$.tw. (6643)
39 double blind$.tw. (42229)
40 ((treble or triple) adj blind$).tw. (480)
41 placebo$.tw. (70811)
42 prospective study/ (221821)
43 or/25-42 (570137)
44 case study/ (27298)
45 case report.tw. (98676)
46 abstract report/ or letter/ (171138)
47 or/44-46 (293801)
48 43 not 47 (558286)











60 50 or 51 or 52 or 53 or 54 or 55 or 56 or 57 or 58 or 59 (2654076)
61 49 and 60 (213)
1.6 Health Management Information Consortium (HMIC) via Ovid search strategy
HMIC search strategy (sea date = 6th February 2019, 12 records
<1979 to November 2018>)
1 designer drugs/ (6)
2 exp. narcotics/ (368)
3 ((substance$ or drug$ or narcotic$) adj2 (addict$ or depend$ or disorder$ or abuse$ or abusing or misuse$ or
misusing or consumption$ or withdraw$ or withdraw$ or detox$)).ti,ab. (3065)
4 (mdma or alcohol$ or opiate$ or opioid$ or opium or heroin or methadone or cocaine or amphetamine$ or
marijuana or cannabis or crack or phencyclidine).ti,ab. (6988)
5 1 or 2 or 3 or 4 (9104)
6 crime/ (455)
7 prisoners/ (660)
8 (justice system or remand$ or parole$ or probation or court$ or corrections or correctional or
revocation).ti,ab. (3355)
9 (offend$ or criminal$ or convict$ or felon$).ti,ab. (2890)
10 (custody or custodial or gaol$ or jail$ or prison$ or incarcerat$ or inmate$).ti,ab. (2360)
11 (reoffend$ or reincarcerat$ or recidiv$ or ex-offender$).ti,ab. (108)
12 6 or 7 or 8 or 9 or 10 or 11 (7182)
13 5 and 12 (642)
14 (“2018” or “2019”).yr. (1340)
15 13 and 14 (1)
16 (2018* or 2019*).dp. (0)
17 (2018* or 2019*).up. (5221)
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18 13 and 17 (12)
19 15 or 18 (12)
1.7 LILACS search strategy
LILACS search strategy (search date = 6th February 2019, 15 records)
tw:((remand or prison or prisoner or prisoners or prisäo or cárcere or cárcel or detenidos or detentas or
acusados or presidiáriossobre or presidiarias or preso or Privados or recluses or offender$ or infratoras or
infratora or infratores or delicuentes or infrator or criminal$ or probation or probatorio or estagio or court or
courts or tribunal or tribunals or secure establishment$ or secure facilit$ or reoffend$ or reincarcerat$ or
recidivi$ or reincidencia or recidivante or reincidência or ex-offender$ or jail or jails or gaol or gaols or
incarcerat$ or encarcerados or covict or convicts or convicted or felon or felons or conviction$ or
reconviction$ or Convicçöes or convicciones or inmate$ or internos or high security or prisoners or law
enforcement or jurisprudence))) AND (tw:((Substance abuse$ or substance misuse$ or substance use$ or
usuários de substâncias or drug dependanc$ or drug abuse$ or drug use$ or drug misuse$ or drug addict$ or
narcotics addict$ or narcotics use$ or narcotics misuse$ or narcotics abuse$ or chemical dependenc$ or
opiates or heroin or crack or cocaine or amphetamines or cocaine or heroína or opioides or anfetaminas or
opiáceos or opioids or addiction or adicción or adicciones or dependência or farmacodependente or adición
or adiçäo or dependence disorder$ or drug involved or Substance-related disorders or amphetamine-related
disorders or
cocaine-related disorders or marijuana abuse or opioid-related disorders or phencyclidine abuse
1.8 MEDLINE via Ovid search strategy
MEDLINE search strategy (search date=6th February 2019, 223 records
Ovid MEDLINE(R) ALL <1946 to February 04, 2019>)
1 exp. substance related disorders/ (263291)
2 street drugs/ (10346)
3 designer drugs/ (1476)
4 exp. narcotics/ (116718)
5 ((substance$ or drug$ or narcotic$) adj2 (addict$ or depend$ or disorder$ or abuse$ or abusing or misuse$ or
misusing or consumption$ or withdraw$ or withdraw$ or detox$)).ti,ab. (96986)
6 (mdma or alcohol$ or opiate$ or opioid$ or opium or heroin or methadone or cocaine or amphetamine$ or
marijuana or cannabis or crack or phencyclidine).ti,ab. (480977)




11 (justice system or remand$ or parole$ or probation or court$ or corrections or correctional or
revocation).ti,ab. (55358)
12 (offend$ or criminal$ or convict$ or felon$).ti,ab. (36931)
13 (custody or custodial or gaol$ or jail$ or prison$ or incarcerat$ or inmate$).ti,ab. (29129)
14 (reoffend$ or reincarcerat$ or recidiv$ or ex-offender$).ti,ab. (5486)
15 8 or 9 or 10 or 11 or 12 or 13 or 14 (123890)
16 7 and 15 (16320)
17 randomised controlled trial.pt. (475636)
18 controlled clinical trial.pt. (92894)
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19 randomised.ab. (433678)
20 placebo.ab. (195168)




25 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 (4370157)
26 exp. animals/ not humans.sh. (4543138)
27 25 not 26 (3778987)
28 16 and 27 (3686)
29 (2018* or 2019*).dt. (1412794)
30 28 and 29 (183)
31 (“2018” or “2019”).yr. (1444316)
32 28 and 31 (202)
33 30 or 32 (223)
1.10 PAIS via ProQuest search strategy
PAIS search strategy (search date = 6th February 2019, 387 records)
(ti((justice system) OR remand* OR parole* OR probation OR court* OR corrections OR correctional OR
revocation) OR ab((justice system) OR remand* OR parole* OR probation OR court* OR corrections OR
correctional OR revocation) OR ti(crime OR offend* OR criminal OR convict* OR felon*) OR ab(crime
OR offend* OR criminal* OR convict* OR felon*) OR ti(custody OR custodial OR gaol* OR jail* OR
prison* OR incarcerate* OR inmate*) OR ab(custody OR custodial OR gaol* OR jail* OR prison* OR
incarcerate*or inmate*) OR ti(reoffered* OR reincarcerate* OR recidiv* OR ex-offender*) OR
ab(reoffered* OR reincarcerate* OR recidiv* OR ex-offender*)) AND (ti(substance* NEAR/2 (addict* OR
depend* OR disorder* OR abuse* OR abusing OR misuse* OR misusing OR consumption* OR
withdraw* OR withdraw* OR detox*)) OR ab(substance* NEAR/2 (addict* OR depend* OR disorder*
OR abuse* OR abusing OR misuse* OR misusing OR consumption* OR withdraw* OR withdraw* OR
detox*)) OR ti(drug* NEAR/2 (addict* OR depend* OR disorder* OR abuse* OR abusing OR misuse*
OR misusing OR consumption* OR withdraw* OR withdraw* OR detox*)) OR ab(drug* NEAR/2
(addict* OR depend* OR disorder* OR abuse* OR abusing OR misuse* OR misusing OR consumption*
OR withdraw* OR withdraw* OR detox*)) OR ti(narcotic* NEAR/2 (addict* OR depend* OR disorder*
OR abuse* OR abusing OR misuse* OR misusing OR consumption* OR withdraw* OR withdraw* OR
detox*)) OR ab(narcotic* NEAR/2 (addict* OR depend* OR disorder* OR abuse* OR abusing OR
misuse* OR misusing OR consumption* OR withdraw* OR withdraw* OR detox*)) OR ti(mdma OR
alcohol* OR opiate* OR opioid* OR opium OR heroine OR methadone OR cocaine OR amphetamine*
OR marijuana OR cannabis OR crack OR phencyclidine) OR ab(mdma OR alcohol* OR opiate* OR
opioid* OR opium OR heroine OR methadone OR cocaine OR amphetamine* OR marijuana OR cannabis
OR crack OR phencyclidine))
1.11 PsycINFO via OVID search strategy
PsycINFO search strategy (search date=6th February 2019, 461 records
Database: PsycINFO <1806 to January Week 4 2019>)
1 Addiction/ (10001)
2 Drug dependency/ (12348)
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3 Drug Usage/ (17225)
4 Drug Abuse/ (45330)
5 Alcohol Abuse/ (17406)
6 Alcohol rehabiliation/ or drug rehabilitation/ (20161)
7 ((substance$ or drug$ or narcotic$) adj2 (addict$ or depend$ or disorder$ or abuse$ or abusing or misuse$ or
misusing or consumption$ or withdraw$ or withdraw$ or detox$)).ti,ab. (77627)
8 (mdma or alcohol$ or opiate$ or opioid$ or opium or heroin or methadone or cocaine or amphetamine$ or
marijuana or cannabis or crack or phencyclidine).ti,ab. (184141)
9 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 (251016)
10 crime/ (14495)
11 criminal behavior/ (8666)
12 recidivism/ (5524)
13 prisoners/ or prisons/ or incarceration/ (17373)
14 probation/ or parole/ (1918)
15 criminals/ or female criminals/ or male delinquency/ or juvenile delinquency/ (31452)
16 (justice system or remand$ or parole$ or probation or court$ or corrections or correctional or
revocation).ti,ab. (55660)
17 (offend$ or criminal$ or convict$ or felon$).ti,ab. (72593)
18 (custody or custodial or gaol$ or jail$ or prison$ or incarcerat$ or inmate$).ti,ab. (38928)
19 (reoffend$ or reincarcerat$ or recidiv$ or ex-offender$).ti,ab. (8872)
20 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 (147687)
21 (empirical study or treatment outcome clinical trial).md. (2342063)
22 (random$ adj4 trial$).ti,ab. (47794)
23 Placebo/ (5203)
24 (random* or sham or placebo*).ti,ab,hw. (214532)
25 ((singl* or doubl*) adj (blind* or dumm* or mask*)).ti,ab,hw. (24681)
26 21 or 22 or 23 or 24 or 25 (2399281)
27 9 and 20 and 26 (11682)
282,018$.up. (155517)
29 27 and 28 (373)
30 "2018".dp. (142864)
31 27 and 30 (343)
32 "2018".yr. (142864)
33 27 and 32 (343)
34 29 or 31 or 33 (461)
1.12 Science Citation Index via Web of Science search strategy
Science Citation Index viaWeb of Science search strategy (search date = 6th February 2019 638 records
Indexes = SCI-EXPANDED Timespan=1900–2019)
# 1 TOPIC: (substance* NEAR/2 (addict* or depend* or disorder* or abuse* or abusing or misuse* or
misusing or consumption* or withdraw* or withdraw* or detox*) ) OR TOPIC: (drug* NEAR/2 (addict*
or depend* or disorder* or abuse* or abusing or misuse* or misusing or consumption* or withdraw* or
withdraw* or detox*) ) OR TOPIC:(narcotic* NEAR/2 (addict* or depend* or disorder* or abuse* or
abusing or misuse* or misusing or consumption* or withdraw* or withdraw* or detox*))
# 2TOPIC: (mdma or alcohol* or opiate* or opioid* or opium or heroin or methadone or cocaine or
amphetamine* or marijuana or cannabis or crack or phencyclidine)
# 3 #2 OR #1
# 4TOPIC: ("justice system" or remand* or parole* or probation or court* or corrections or correctional or
revocation) OR TOPIC: (crime or criminal or offender* or criminal* or convict* or felon*) OR TOPIC:
(custody or custodial or gaol* or jail* or prison* or incarcerat* or inmate*) OR TOPIC: (reoffend* or
reincarcerat* or recidiv* or ex-offender*)
#5#4 AND #2
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1.12 Social Science Citation Index via Web of Science search strategy
Social Science Citation Index via Web of Science search strategy (search date = 6th February 2019, 757
records, Indexes = SSCI Timespan = 1900–2019)
# 1TOPIC:
(substance* NEAR/2 (addict* or depend* or disorder* or abuse* or abusing or misuse* or misusing or
consumption* or withdraw* or withdraw* or detox*) ) OR TOPIC: (drug* NEAR/2 (addict* or depend* or
disorder* or abuse* or abusing or misuse* or misusing or consumption* or withdraw* or withdraw* or
detox*) ) OR TOPIC: (narcotic* NEAR/2 (addict* or depend* or disorder* or abuse* or abusing or
misuse* or misusing or consumption* or withdraw* or withdraw* or detox*))
# 2TOPIC: (mdma or alcohol* or opiate* or opioid* or opium or heroin or methadone or cocaine or
amphetamine* or marijuana or cannabis or crack or phencyclidine)
# 3#2 OR #1
# 4TOPIC: (“justice system” or remand* or parole* or probation or court* or corrections or correctional or
revocation) OR TOPIC: (crime or criminal or offender* or criminal* or convict* or felon*) OR TOPIC:
(custody or custodial or gaol* or jail* or prison* or incarcerat* or inmate*) OR TOPIC: (reoffend* or
reincarcerat* or recidiv* or ex-offender*)
#5#4 AND #3
2. Screening criteria
The screening process was divided into two key phases. Phase one used seven key
questions reported in the original new reference review:
Prescreening criteria: phase one
Is the document an empirical study? [If "no" exclude document.]
Does the study evaluate an intervention, a component of which is designed to reduce, eliminate or prevent
relapse among drug-using offenders?
Are the participants referred by the criminal justice system at baseline?
Does the study report pre-programme and post-programme measures of drug use?
Does the study report pre-programme and post-programme measures of criminal behaviour?
Is the study a randomised controlled trial?
Do the outcome measures refer to the same length of follow-up for two groups?
Papers included after phase one screening were then scrutinised to assess:
Prescreening: phase two
Is the intervention a pharmacological intervention? [if "yes" include document]
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3. Drummond (1996) checklist—risk of bias assessment tool
for economic evaluations
Study name




1. Was the research question stated?
2. Was the economic importance of the research question stated?
3. Was/were the viewpoint(s) of the analysis clearly stated and justified?
4. Was a rationale reported for the choice of the alternative programmes
or interventions compared?
5. Were the alternatives being compared clearly described?
6. Was the form of economic evaluation stated?
7. Was the choice of form of economic evaluation justified in relation to
the questions addressed?
Data collection
8. Was/were the source(s) of effectiveness estimates used stated?
9. Were details of the design and results of the effectiveness study given
(if based on a single study)?
10. Were details of the methods of synthesis or meta-analysis of estimates
given (if based on an overview of a number of effectiveness studies)?
11. Were the primary outcome measure(s) for the economic evaluation
clearly stated?
12. Were the methods used to value health states and other benefits
stated?
13. Were the details of the subjects from whom valuations were obtained
given?
14. Were productivity changes (if included) reported separately?
15. Was the relevance of productivity changes to the study question
discussed?
16. Were quantities of resources reported separately from their unit cost?
17. Were the methods for the estimation of quantities and unit costs
described?
18. Were currency and price data recorded?
19. Were details of price adjustments for inflation or currency conversion
given?
20. Were details of any model used given?
21. Was there a justification for the choice of model used and the key
parameters on which it was based?
Analysis and interpretation of results
22. Was the time horizon of cost and benefits stated?
23. Was the discount rate stated?
24. Was the choice of rate justified?
25. Was an explanation given if cost or benefits were not discounted?
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26. Were the details of statistical test(s) and confidence intervals given for
stochastic data?
27. Was the approach to sensitivity analysis described?
28. Was the choice of variables for sensitivity analysis justified?
29. Were the ranges over which the parameters were varied stated?
30. Were relevant alternatives compared? (That is, were appropriate
comparisons made when conducting the incremental analysis?)
31. Was an incremental analysis reported?
32. Were major outcomes presented in a disaggregated as well as
aggregated form?
33. Was the answer to the study question given?
34. Did conclusions follow from the data reported?
35. Were conclusions accompanied by the appropriate caveats?
36. Were generalisability issues addressed?
Adapted from Drummond MF, Jefferson TO (1996) Guidelines for authors and peer reviewers of economic
submissions to the BMJ. The BMJ Economic Evaluation Working Party. British Medical Journal 313
(7052): 275–83. Cited in Centre for Reviews and Dissemination (2008) Systematic reviews. CRD’s
guidance for undertaking reviews in health care. York: Centre for Reviews and Dissemination
4. Drummond (2005) classification scheme for economic evaluations
Are both costs (inputs) and consequences (outputs) of the alternative examined?
Are two or more
alternatives compared?
No No Yes









Yes PARTIAL EVALUATION FULL ECONOMIC
EVALUATION (4)
Efficacy effectiveness
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5. Risk of bias assessments of randomised controlled trials—criteria
for judging risk of bias assessments
Item Judgement Description
1. Random sequence generation (selection
bias)
Low risk The investigators describe a random component
in the sequence generation process such as
random number table; computer random
number generator; coin tossing; shuffling
cards or envelopes; throwing dice; drawing of
lots; minimisation.
High risk The investigators describe a non-random com-
ponent in the sequence generation process
such as odd or even date of birth; date (or
day) of admission; hospital or clinic record
number; alternation; judgement of the clini-
cian; results of a laboratory test or a series of
tests; availability of the intervention.
Unclear
risk
Insufficient information about the sequence
generation process to permit judgement of
low or high risk.
2. Allocation concealment (selection bias) Low risk Investigators enrolling participants could not
foresee assignment because one of the
following, or an equivalent method, was used
to conceal allocation: central allocation
(including telephone, web-based, and
pharmacy-controlled randomisation); se-
quentially numbered drug containers of
identical appearance; sequentially numbered,
opaque, sealed envelopes.
High risk Investigators enrolling participants could
possibly foresee assignments because one of
the following method was used: open random
allocation schedule (e.g. a list of random
numbers); assignment envelopes without
appropriate safeguards (e.g. if envelopes were
unsealed or non-opaque or not sequentially
numbered); alternation or rotation; date of




Insufficient information to permit judgement of
low or high risk. This is usually the case if the
method of concealment is not described or
not described in sufficient detail to allow a
definite judgement.
3. Blinding of participants and providers
(performance bias) Objective outcomes
Low risk No blinding or incomplete blinding, but the
review authors judge that the outcome is not
likely to be influenced by lack of blinding;
blinding of participants and key study
personnel ensured, and unlikely that the
blinding could have been broken.
High risk No blinding or incomplete blinding, and the
outcome is likely to be influenced by lack of
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blinding; blinding of key study participants
and personnel attempted, but likely that the
blinding could have been broken, and the




Insufficient information to permit judgement of
low or high risk; the study did not address
this outcome.
4. Blinding of participants and providers
(performance bias)—subjective outcomes
Low risk Blinding of participants and providers and
unlikely that the blinding could have been
broken;
High risk No blinding or incomplete blinding, and the
outcome is likely to be influenced by lack of
blinding; blinding of key study participants
and personnel attempted, but likely that the
blinding could have been broken, and the




Insufficient information to permit judgement of
low or high risk; the study did not address
this outcome.
5. Blinding of outcome assessor (detection
bias)—objective outcomes
Low risk No blinding of outcome assessment, but the
review authors judge that the outcome
measurement
is not likely to be influenced by lack of blinding;
blinding of outcome assessment ensured, and
unlikely that the blinding could have been
broken.
High risk No blinding or incomplete blinding, and the
outcome is likely to be influenced by lack of
blinding; blinding of key study participants
and personnel attempted, but likely that the
blinding could have been broken, and the




Insufficient information to permit judgement of
low or high risk; the study did not address
this outcome.
6.Blinding of outcome assessor (detection
bias)—subjective outcomes
Low risk No blinding of outcome assessment, but the
review authors judge that the outcome
measurement is not likely to be influenced by
lack of blinding; blinding of outcome
assessment ensured, and unlikely that the
blinding could have been broken.
High risk No blinding of outcome assessment, and the
outcome measurement is likely to be
influenced by lack of blinding; blinding of
outcome assessment, but likely that the
blinding could have been broken, and the
outcome measurement is likely to be
influenced by lack of blinding.
Unclear
risk
Insufficient information to permit judgement of
low or high risk.
Low risk No missing outcome data; reasons for missing
outcome data unlikely to be related to true
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7. Incomplete outcome data (attrition bias)—
for all outcomes except retention in
treatment or drop out
outcome (for survival data, censoring
unlikely to be introducing bias); missing
outcome data balanced in numbers across
intervention groups, with similar reasons for
missing data across groups; for dichotomous
outcome data, the proportion of missing
outcomes compared with observed event risk
not enough to have a clinically relevant
impact on the intervention effect estimate; for
continuous outcome data, plausible effect
size (difference in means or standardised
difference in means) among missing
outcomes not enough to have a clinically
relevant impact on observed effect size;
missing data have been imputed using
appropriate methods; all randomised patients
are reported/analysed in the group they were
allocated to by randomisation irrespective of
non-compliance and co-interventions (inten-
tion to treat)
High risk Reason for missing outcome data likely to be
related to true outcome, with either imbalance
in numbers or reasons for missing data across
intervention groups;
for dichotomous outcome data, the proportion of
missing outcomes compared with observed
event risk enough to induce clinically
relevant bias in intervention effect estimate;
for continuous outcome data, plausible effect
size (difference in means or standardised
difference in means) among missing
outcomes enough to induce clinically
relevant bias in observed effect size;
“As-treated” analysis done with substantial
departure of the intervention received from
that assigned at randomisation.
Unclear
risk
Insufficient information to permit judgement of
low or high risk (e.g. number randomised not
stated, no reasons for missing data provided;
number of drop out not reported for each
group).
8. Selective reporting (reporting bias) Low risk The study protocol is available and all of the
study’s pre-specified (primary and second-
ary) outcomes that are of interest in the re-
view have been reported in the pre-specified
way; the study protocol is not available but it
is clear that the published reports include all
expected outcomes, including those that were
pre-specified (convincing text of this nature
may be uncommon).
High risk Not all of the study’s pre-specified primary
outcomes have been reported; one or more
primary outcomes is reported using
measurements, analysis methods or subsets of
the data (e.g. sub scales) that were not pre--
specified.
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Unclear
risk
One or more reported primary outcomes were
not pre-specified (unless clear justification for
their reporting is provided, such as an unex-
pected adverse effect); one or more outcomes
of interest in the review are reported incom-
pletely so that they cannot be entered in a
meta-analysis; the study report fails to include
results for a key outcome that would be ex-
pected to have been reported for such a study.
9. Other bias Low risk Evidence to suggest other problems identified
with the study which might threaten the
validity of the random allocation, attrition or
data integrity and results of the trial.
High risk Evidence to suggest that the trial might be
underpowered/problems with the random al-
location process leading to potential
self-selection bias/ issues of analysis not
conducted using intent to treat analysis or
evidence of missing data; concerns of attri-
tion and measurement error including reli-
ance on self-reported measures.
Unclear
risk
Insufficient information to permit judgement of
low or high risk.
6. Risk of bias of RCTs: summary of the assessments
Risk of bias domain summaries
Random sequence Although all the included studies were randomised trials, nearly 50% (10/22) provided
an inadequate description and were rated as unclear by the reviewers (Brodie et al.,
2009, Brown et al., 2013, Cornish et al., 1997, Coviello et al., 2010, Hanlon et al.,
1975, Hanlon et al., 1977, Howells et al., 2002, Kinlock et al., 2005, Kurland et al.,
1975, Parmar et al., 2017). Eleven studies were reported at low risk of bias
(Bayanzadeh, 2004, Dolan et al., 2003, Dole et al., 1969, Kinlock et al., 2007,
Konstenius et al., 2014, Lee et al., 2016, Lobmaier et al., 2010, Magura et al., 2009,
McKenzie et al., 2012, Rich et al., 2015, Wright et al., 2011) and the remaining
study was at high risk of bias (Cropsey et al., 2011).
Allocation
concealment
Of the 22 included studies, five reported that the allocation process was concealed and
were rated at low risk of bias (Dolan et al., 2003, Konstenius et al., 2014, Lee et al.,
2016, Lobmaier et al., 2010, Wright et al., 2011). Five studies were rated at high risk
of bias (Bayanzadeh, 2004, Cropsey et al., 2011, Magura et al., 2009, McKenzie
et al., 2012, Rich et al., 2015). The remaining 12 studies were all rated as unclear
(Brodie et al., 2009, Brown et al., 2013, Cornish et al., 1997, Dole et al., 1969,
Hanlon et al., 1975, Hanlon et al., 1977, Howells et al., 2002, Kinlock et al., 2005,
Kinlock et al., 2007, Konstenius et al., 2014, Kurland et al., 1975, Parmar et al.,
2017) and the review authors were unable to decide whether allocation concealment
had occurred within the studies.
Blinding Blinding was assessed across four dimensions considering performance and detection
bias across subjective and objective measures. Seven studies were rated as unclear
risk of bias and provided no information on blinding across all four domains
(Bayanzadeh, 2004, Brown et al., 2013, Cropsey et al., 2011, Dole et al., 1969,
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Kinlock et al., 2005, Kinlock et al., 2007, Magura et al., 2009). Eight studies were
rated at high risk of bias for participant and personnel blinding (Cornish et al., 1997,
Coviello et al., 2010, Dolan et al., 2003, Lee et al., 2016, Lobmaier et al., 2010,
McKenzie et al., 2012, Rich et al., 2015, Wright et al., 2011). Seven studies reported
use of a double-blind trial methodology and were rated low risk of bias (Brodie et al.,
2009, Hanlon et al., 1975, Hanlon et al., 1977, Howells et al., 2002, Konstenius
et al., 2014, Kurland et al., 1975, Parmar et al., 2017).
Incomplete outcome
data
Three studies were noted at low risk of bias (Cornish et al., 1997, Dole et al., 1969,
Kinlock et al., 2007) and 18 studies were noted to be at high risk of bias
(Bayanzadeh, 2004, Brodie et al., 2009, Brown et al., 2013, Coviello et al., 2010,
Cropsey et al., 2011, Dolan et al., 2003, Hanlon et al., 1975, Hanlon et al., 1977,
Howells et al., 2002, Kinlock et al., 2005, Konstenius et al., 2014, Lee et al., 2016,
Lobmaier et al., 2010, Magura et al., 2009, McKenzie et al., 2012, Parmar et al.,
2017, Rich et al., 2015, Wright et al., 2011). One study was rated as unclear risk of
bias (Kurland et al., 1975).
Selective reporting Of the 20 studies, six studies were rated as unclear (Bayanzadeh, 2004, Cropsey et al.,
2011, Dole et al., 1969, Hanlon et al., 1977, Kinlock et al., 2005, Kurland et al.,
1975) and twelve studies were rated at low risk (Cornish et al., 1997, Coviello et al.,
2010, Dolan et al., 2003, Howells et al., 2002, Kinlock et al., 2007, Konstenius
et al., 2014, Lee et al., 2016, Lobmaier et al., 2010, Magura et al., 2009, McKenzie
et al., 2012, Rich et al., 2015, Wright et al., 2011). Four studies were rated at high
risk of bias (Brodie et al., 2009, Brown et al., 2013, Hanlon et al., 1975, Parmar
et al., 2017).








Low risk Participants were categorised into one of four lists
based on their previous history of drug abuse. The
random allocation was then chosen, using even
and odd row numbers from each list
Allocation concealment (selection
bias)
High risk The lists generated with stratification were probably
not concealed
Blinding of participants and personnel
(performance bias) subjective
outcomes
Unclear risk No information reported
Blinding of participants and personnel
(performance bias) objective
outcomes
Unclear risk No information on blinding reported
Blinding of outcome assessment
(detection bias) subjective
outcomes
Unclear risk No information on blinding reported
Blinding of outcome assessment
(detection bias) objective outcomes
Unclear risk No information on blinding reported
High risk
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Incomplete outcome data (attrition
bias) all outcomes
After random allocation, 20 participants from the
control group opted out of the research. At the end
of the study attrition was high in both groups: for
the intervention group n = 38 out of the original 60
allocated and for the control group n = 31 out of
the original 60 allocated.








Unclear risk Method for random sequence generation not reported
Allocation concealment (selection
bias)
Unclear risk Method for allocation of participants to treatment
groups not reported
Blinding of participants and personnel
(performance bias) subjective
outcomes
Low risk Staff, and personnel were both blind to treatment.
Blinding of participants and personnel
(performance bias) objective
outcomes
Low risk Staff and personnel were both blind to treatment
Blinding of outcome assessment
(detection bias) subjective
outcomes
Unclear risk Blinding of outcome assessors not reported
Blinding of outcome assessment
(detection bias) objective outcomes
Unclear risk Blinding of outcome assessors not reported
Incomplete outcome data (attrition
bias) all outcomes
High risk 38% in the vigabatrin group and 58.5% in the
placebo group were lost to follow-up. Outcomes
reported for n randomised. Missing urine
toxicology tests were considered positive.
Selective reporting (reporting bias) High risk Protocol identified for trial registration
NCT00527683. Primary and secondary outcomes
are clearly stated but some secondary mental








Unclear risk Random allocation noted no further information.
Allocation concealment (selection
bias)
Unclear risk No information provided
Blinding of participants and personnel
(performance bias) subjective
outcomes
Unclear risk No information provided
Blinding of participants and personnel
(performance bias) objective
outcomes
Unclear risk No information provided
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Blinding of outcome assessment
(detection bias) subjective
outcomes
Unclear risk No information provided
Blinding of outcome assessment
(detection bias) objective outcomes
Unclear risk No information provided
Incomplete outcome data (attrition
bias) all outcomes
High risk 80% completing the 24-week assessment, 33%
completing week 52 and 26% at follow-up.
Selective reporting (reporting bias) High risk Protocol reported as being available. However,
on-going drug use (frequency and patterns of daily
drug use), health services utilisation and urine
tests are reported as being assessed, but no out-






Random sequence generation (selection
bias)
Unclear risk Individuals were assigned at a ratio of 2:1 to
naltrexone vs control
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias) subjective outcomes
High risk Study description suggests that participants
were not blind
Blinding of participants and personnel
(performance bias) objective outcomes
High risk Study description suggests that participants
were not blind
Blinding of outcome assessment (detection
bias) subjective outcomes
Unclear risk No information was reported on whether the
subjective measures were blinded
Blinding of outcome assessment (detection
bias) objective outcomes
Low risk Outcome assessors were blind
Incomplete outcome data (attrition bias) all
outcomes
Low risk ITT analyses completed.








Unclear risk Randomisation method unclear. Note that
randomisation was balanced by using six variables
Allocation concealment (selection
bias)
Unclear risk No information provided
Blinding of participants and personnel
(performance bias) subjective
outcomes
High risk The treatment as usual group were not blinded
Blinding of participants and personnel
(performance bias) objective
outcomes
High risk The treatment as usual group were not blinded
Blinding of outcome assessment
(detection bias) subjective
outcomes
Unclear risk No information was reported on whether the
subjective measures were blinded
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Blinding of outcome assessment
(detection bias) objective outcomes
Unclear risk No information was reported on whether the
objective measures were blinded
Incomplete outcome data (attrition
bias) all outcomes
High risk A large amount of attrition was noted in the first
week, and only one-third of participants remained
at 6-month follow-up








High risk The first 9 participants deliberately allocated to
intervention for practical reasons. Subsequently a
random number table was used to allocate the
remaining sample to the intervention or placebo.
Allocation concealment (selection
bias)
High risk First 9 participants deliberately allocated to
intervention for practical reasons. Use of sealed
envelopes for the remaining sample
Blinding of participants and personnel
(performance bias) subjective
outcomes
Unclear risk This trial began as an open label trial then became a
double-blind trial of participants and providers on
all outcomes. Some concerns about contamination
issues with the placebo group but difficult to
assess to what extent the blinding might have been
affected.
Blinding of participants and personnel
(performance bias) objective
outcomes
Unclear risk This trial began as an open label trial then became a
double-blind trial of participants and providers on
all outcomes. Some concerns about contamination
issues with the placebo group but difficult to
assess to what extent the blinding might have been
affected.
Blinding of outcome assessment
(detection bias) subjective
outcomes
Unclear risk No evidence to provide information about whether
the assessors who conducted the outcome
assessments were blind
Blinding of outcome assessment
(detection bias) objective outcomes
Unclear risk No evidence to provide information about whether
the assessors who conducted the outcome
assessments were blind
Incomplete outcome data (attrition
bias) all outcomes
Unclear risk A total of 8 individuals (22%) were not included in
the final analysis after randomisation. It is unclear
whether an ITT analyses was conducted.








Low risk Group allocation was based on block randomisation.
A sequential list of case numbers was matched to
group allocations in blocks of ten by randomly
drawing five cards labelled “control” and five
cards labelled “treatment” from an envelope. This
procedure was repeated for each block of ten
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sequential case numbers. The list of case numbers
and group allocation was held by a researcher not
involved in recruiting or interviewing inmates.
The trial nurses responsible for assessing,




Low risk Allocation held by researcher not involved in
recruiting or interviewing participants. Trial
nurses had no access to lists
Blinding of participants and personnel
(performance bias) subjective
outcomes
High risk Treatment and comparator (methadone or wait list)
would not permit blinding
Blinding of participants and personnel
(performance bias) objective
outcomes
High risk Treatment and comparator (methadone or wait list)
would not permit blinding
Blinding of outcome assessment
(detection bias) subjective
outcomes
Unclear risk No information was provided
Blinding of outcome assessment
(detection bias) objective outcomes
Unclear risk No information was provided
Incomplete outcome data (attrition
bias) all outcomes
High risk Attrition > 30% in both groups and ITT not
undertaken. At follow-up, 129 (68%) treated and
124 (65%) control subjects who had been in
continuous custody were re-interviewed. 29
treated and 33 control subjects had been released
from prison and were excluded. No data on other
participants not accounted for at follow-up





Random sequence generation (selection bias) Low risk Allocation by lottery, no further details of
the study method provided
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias) subjective outcomes
Unclear risk No information provided
Blinding of participants and personnel
(performance bias) objective outcomes
Unclear risk No information provided
Blinding of outcome assessment (detection
bias) subjective outcomes
Unclear risk No information provided
Blinding of outcome assessment (detection
bias) objective outcomes
Unclear risk No information provided
Incomplete outcome data (attrition bias) all
outcomes
Low risk No attrition reported on any of the key
outcome measures
Selective reporting (reporting bias) Unclear risk Protocol for the trial not identified.
Hanlon 1975
Bias Support for judgement






Unclear risk Reported as randomly assigned no details provided
Allocation concealment (selection
bias)
Unclear risk Not reported
Blinding of participants and personnel
(performance bias) subjective
outcomes
Low risk Reported as double-blind study
Blinding of participants and personnel
(performance bias) objective
outcomes
Low risk Reported as double-blind study
Blinding of outcome assessment
(detection bias) subjective
outcomes
Unclear risk Not reported in the study
Blinding of outcome assessment
(detection bias) objective outcomes
Unclear risk Not reported in the study
Incomplete outcome data (attrition
bias) all outcomes
High risk Attrition across the two groups was high. In the
intervention group 21 (60%) people did not
complete the intervention and in the comparison
intervention 17(48.6%) did not complete the
intervention. No intent to treat analysis is
provided.
Selective reporting (reporting bias) High risk Primary and secondary outcomes are not reported
separately. No trial protocol is reported. The
results were divided into those who completed and








Unclear risk Not reported
Allocation concealment (selection
bias)
Unclear risk Not reported
Blinding of participants and personnel
(performance bias) subjective
outcomes
Low risk Reported as a double-blind trial
Blinding of participants and personnel
(performance bias) objective
outcomes
Low risk Reported as a double-blind trial
Blinding of outcome assessment
(detection bias) subjective
outcomes
Unclear risk Not reported
Blinding of outcome assessment
(detection bias) objective outcomes
Unclear risk Not reported
Incomplete outcome data (attrition
bias) all outcomes
High risk Of the original 154 parolees referred and assigned to
one of the two treatment arms—57 did not receive
study medication and were excluded. This re-
duced the resulting sample size on which the
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analyses were performed to 55 in the intervention
group and 42 in the placebo group.








Unclear risk The authors report “The pharmacist who made up the
medication used a simple randomisation
procedure to allocate each participant to one arm
of the trial” but no further description is reported.
Allocation concealment (selection
bias)
Unclear risk The authors report “The independent pharmacy team
at the prison oversaw the randomisation and
blinding procedure…”, but no statement that
allocation was concealed
Blinding of participants and personnel
(performance bias) subjective
outcomes
Low risk “…both the patient and health centre clinicians were
blind to the assigned treatment group”
Blinding of participants and personnel
(performance bias) objective
outcomes
Low risk “…both the patient and health centre clinicians were
blind to the assigned treatment group”
Blinding of outcome assessment
(detection bias) subjective
outcomes
Low risk “…blinding was maintained during treatment of the
patients and during data entry and analysis”
Blinding of outcome assessment
(detection bias) objective outcomes
Low risk “…blinding was maintained during treatment of the
patients and during data entry and analysis”
Incomplete outcome data (attrition
bias) all outcomes
High risk Twenty-one participants (27.63%) (13/32 lofexidine,
8/36 methadone) were withdrawn from the trial
prematurely. ITT not used, data analysed
per-protocol
Selective reporting (reporting bias) Low risk The authors indicate that there was a protocol for the
study (“Patient safety elements in the protocol
were as follows:”) and primary and secondary
outcomes are clearly defined. Outcome data for








Unclear risk No information reported other than stated ‘random’
Allocation concealment (selection bias) Unclear risk No information reported
Blinding of participants and personnel
(performance bias) subjective
outcomes
Unclear risk No information reported
Blinding of participants and personnel
(performance bias) objective
outcomes
Unclear risk No information reported
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Blinding of outcome assessment
(detection bias) subjective outcomes
Unclear risk No information reported
Blinding of outcome assessment
(detection bias) objective outcomes
Unclear risk No information reported
Incomplete outcome data (attrition
bias) all outcomes
High risk Follow-up interviews were conducted on 66, or
80% of the 83 participants who were eligible; 22
of 26 experimental participants (85%), 31 of 38
control participants (82%), and 13 of 19 who
declined participation in the experimental
condition (68%).








Low risk Block randomisation
Allocation concealment (selection
bias)
Unclear risk No information reported
Blinding of participants and personnel
(performance bias) subjective
outcomes
Unclear risk No information reported
Blinding of participants and personnel
(performance bias) objective
outcomes
Unclear risk No information reported
Blinding of outcome assessment
(detection bias) subjective
outcomes
Unclear risk No information reported
Blinding of outcome assessment
(detection bias) objective outcomes
Unclear risk No information reported
Incomplete outcome data (attrition
bias) all outcomes
Low risk One month post-release follow-up assessments were
conducted on 200, or 96.2% of the 208 partici-
pants due for this assessment; 64 of 70 (91.4%) in
the counselling only condition, 66 of 68 (97.1%)
in the counselling + transfer condition, and 70 of
70 (100.0%) in the counselling + methadone
condition









Low risk The randomisation list was generated by an
independent pharmacist using the computer-based
programme design by Trombult Programming
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The randomisation code was retained by the
Karolinska Pharmacy and disclosed after the end
of the trial. No interim analysis was performed.
Blinding of participants and personnel
(performance bias) subjective
outcomes
Low risk Although efforts were made to maintain blinding,
48% of the participants receiving MPH and 48%
of the placebo group identified their medication
correctly during the titration phase or after
reaching the maximum dose.
Blinding of participants and personnel
(performance bias) objective
outcomes
Low risk Although efforts were made to maintain blinding,
48% of the participants receiving MPH and 48%
of the placebo group identified their medication
correctly during the titration phase or after
reaching the maximum dose.
Blinding of outcome assessment
(detection bias) subjective
outcomes
Unclear risk Not reported if assessor was blind
Blinding of outcome assessment
(detection bias) objective outcomes
Unclear risk Not reported if assessor was blind
Incomplete outcome data (attrition
bias) all outcomes
High risk > 10% in both groups did not complete the trial,
more in the placebo group than the intervention
group.
Selective reporting (reporting bias) Low risk The trial was registered in the International Standard
Randomised Controlled Trial Number Register







Random sequence generation (selection bias) Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias) subjective outcomes
Low risk Reported as double-blind trial
Blinding of participants and personnel
(performance bias) objective outcomes
Low risk Reported as double-blind trial
Blinding of outcome assessment (detection
bias) subjective outcomes
Unclear risk Not reported
Blinding of outcome assessment (detection
bias) objective outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias) all
outcomes
Unclear risk Reporting is given by group but no
reasons for withdrawal are provided
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An independent, centralised, automated telephone
system made the treatment assignments after
eligibility of the participants was confirmed
Allocation concealment (selection
bias)
Low risk Sealed envelopes were sequenced and shuffled.
Participants and researchers could not foresee
assignment.
Blinding of participants and personnel
(performance bias) subjective
outcomes
High risk This is an open trial no blinding was conducted
Blinding of participants and personnel
(performance bias) objective
outcomes
High risk This is an open trial no blinding was conducted
Blinding of outcome assessment
(detection bias) subjective
outcomes
High risk This is an open trial no blinding was conducted
Blinding of outcome assessment
(detection bias) objective outcomes
High risk This is an open trial no blinding was conducted
Incomplete outcome data (attrition
bias) all outcomes
High risk 13% were lost to follow-up in the naltrexone group
and 8% in usual care, and some outcomes were
only available for completers.
Selective reporting (reporting bias) Low risk Trial protocol NCT 00781898 is registered and









Low risk Treatment allocation sequence performed at an




Low risk Sequentially numbered, sealed, opaque envelopes
Blinding of participants and personnel
(performance bias) subjective
outcomes
High risk “the treatment conditions were not blind and may
have increased risk of performance bias”
Blinding of participants and personnel
(performance bias) objective
outcomes
High risk “the treatment conditions were not blind and may
have increased risk of performance bias”
Blinding of outcome assessment
(detection bias) subjective
outcomes
Unclear risk No information provided
Blinding of outcome assessment
(detection bias) objective outcomes
Unclear risk No information provided
Incomplete outcome data (attrition
bias) all outcomes
High risk In the naltrexone implant arm of the trial, 7 of 23
inmates did not initiate treatment: all 7 reported a
preference for methadone or a non-study treat-
ment. In the methadone treatment arm, 10 of 21
inmates did not initiate treatment and dropped out
before release: 60% of the methadone group
drop-outs reported that they intended to start, but
were not granted the possibility to continue with
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methadone maintenance upon release by commu-
nity treatment providers.
Selective reporting (reporting bias) Low risk The study was funded by the Research Council of
Norway and registered publicly at
http://clinicaltrials.gov, identifier NCT00204243.








Low risk Random number generator used. Allocation was
originally 1:1, but loss in one group meant that




High risk Project director was naive to allocation, but research
assistant was not
Blinding of participants and personnel
(performance bias) subjective
outcomes
Unclear risk No information provided
Blinding of participants and personnel
(performance bias) objective
outcomes
Unclear risk No information provided
Blinding of outcome assessment
(detection bias) subjective
outcomes
Unclear risk No information provided
Blinding of outcome assessment
(detection bias) objective outcomes
Unclear risk No information provided
Incomplete outcome data (attrition
bias) all outcomes
High risk Some attrition occurred before medication was
received by buprenorphine-assigned participants.
Interview follow-ups were attempted for 60
buprenorphine subjects, of whom 43 (72%) were
interviewed at follow-up, and for 56 methadone
subjects, of whom 38 (68%) were interviewed.
Selective reporting (reporting bias) Low risk The study was approved by the Institutional Review
Boards of National Development and Research
Institutes (NDRI) and DOHMH. The
ClinicalTrials.gov identifier is NCT00367302.









Low risk Computer-generated random permutation. Urn




High risk Open-label trial no mention of blinding
High risk Open-label trial no mention of blinding
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Blinding of participants and personnel
(performance bias) subjective
outcomes
Blinding of participants and personnel
(performance bias) objective
outcomes
High risk Open-label trial no mention of blinding
Blinding of outcome assessment
(detection bias) subjective
outcomes
Unclear risk The assessment of outcomes was not described
Blinding of outcome assessment
(detection bias) objective outcomes
Unclear risk The assessment of outcomes was not described
Incomplete outcome data (attrition
bias) all outcomes
High risk There was substantial cross over from arms 1 and 3
to 2. The authors suggested that the treatment
completer analysis is more reliable than the ITT
analysis. Data for the completers only are
presented.
Selective reporting (reporting bias) Low risk Protocol and trial is registered see NCT00142935.












Unclear risk Allocation concealment not reported
Blinding of participants and personnel
(performance bias) subjective
outcomes
Low risk The trial was double-blind prior to release so that,
whilst the participant was still in custody and
pre-release, neither the participant, prison-based
N-ALIVE staff nor prison staff knew the alloca-
tion. Participants learned their allocation when
they opened the pack at the time of their release.
Blinding of participants and personnel
(performance bias) objective
outcomes
Low risk The trial was double-blind prior to release so that,
whilst the participant was still in custody and
pre-release, neither the participant, prison-based
N-ALIVE staff nor prison staff knew the alloca-
tion. Participants learned their allocation when
they opened the pack at the time of their release.
Blinding of outcome assessment
(detection bias) subjective
outcomes
High risk The self-reported questionnaire identified the partic-
ipant’s randomised assignment and the time in-
terval between the preceding N-ALIVE release
date and completion date.
Blinding of outcome assessment
(detection bias) objective outcomes
Unclear risk Not applicable—no objective measures reported in
the trial.
Incomplete outcome data (attrition
bias) all outcomes
High risk Approximately 20% attrition in each group—due to
those allocated did not get their allocation as
intended.
Selective reporting (reporting bias) High risk Study protocol is reported but not all of the study’s
pre-specified primary outcomes have been report-
ed due to the trial stopping early. Protocol
(ISRCTN34044390)








Low risk Computer generated random permutation. Urn
randomisation to stratify on the basis of sex and
race. Independent of enrolment and consent
process. Random assignment was obtained from a




High risk No blinding conducted using an open-label trial
design
Blinding of participants and personnel
(performance bias) subjective
outcomes
High risk No blinding conducted using an open-label trial
design
Blinding of participants and personnel
(performance bias) objective
outcomes
High risk No blinding conducted using an open-label trial
design
Blinding of outcome assessment
(detection bias) subjective
outcomes
Unclear risk Blinding of outcome measures not clearly reported
Blinding of outcome assessment
(detection bias) objective outcomes
Unclear risk Blinding of outcome measures not clearly reported
Incomplete outcome data (attrition
bias) all outcomes
High risk In the methadone continuation group data were
available for 114/142 (80%). In the tapered with-
drawal group data were available for 109/141
(77%). There is some attrition.
Selective reporting (reporting bias) High risk Study protocol is reported and all of specified








Low risk Randomisation sequence (with random block size)




Low risk Sealed, opaque, consecutively numbered envelopes
concealing the name of the allocated intervention
were prepared by a researcher who had no contact
with participants.
Blinding of participants and personnel
(performance bias) subjective
outcomes
High risk Open label “The prescribing doctor randomised by
opening the next envelope and prescribing the
intervention named inside. Both prisoner and
doctor were blind to the intervention until this
point”.
Blinding of participants and personnel
(performance bias) objective
outcomes
High risk Open label “The prescribing doctor randomised by
opening the next envelope and prescribing the
intervention named inside. Both prisoner and
doctor were blind to the intervention until this
point”.
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Blinding of outcome assessment
(detection bias) subjective
outcomes
Unclear risk No statement regarding blinding of individual who
undertook the biochemical urine tests.
Blinding of outcome assessment
(detection bias) objective outcomes
Unclear risk No statement regarding blinding of individual who
recorded self-reported or clinical notes.
Incomplete outcome data (attrition
bias) all outcomes
High risk High levels of attrition. 50% buprenorphine and 45%
methadone did not provide urine sample at day 8.
65% and 62% at 1 month, 80% and 85% at
3 months and 86% and 91% at 6 months.
Selective reporting (reporting bias) Low risk Published study protocol identified. All primary and
secondary outcomes reported.
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